[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Advanced Medical Solutions Ltd.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":135},{"warningLetters":4,"total":134},[5,31,53,74,95,114],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},3123,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2021-10-05T13:20:00Z\">10\u002F05\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-09-29T04:00:00Z\">09\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftrue-chemical-solutions-llc-616672-09292021\">True Chemical Solutions, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Failure to Permit Access to or Copying of Records","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Travis Pitcock\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>True Chemical Solutions, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6215 W. County Road 112\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Midland\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>79706\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-21-60\u003C\u002Fp>\n\n\u003Cp>September 29, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Pitcock:\u003C\u002Fp>\n\n\u003Cp>Your firm is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products; specifically, products listed include HAPPY HANDS Hand Sanitizer Topical Gel with Moisturizing Solution. On November 10, 2020, the FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file. This request went unanswered, as did numerous telephone calls from the Agency regarding this matter, so the Agency sent a follow-up written request for such records and other information by certified return-receipt mail on May 4, 2021. Delivery was confirmed by your signature, but you failed to respond to these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request and follow-up communication included a sufficient and clear description of the records sought.\u003C\u002Fp>\n\n\u003Cp>It is a prohibited act under section 301(e) of the FD&amp;C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a).\u003C\u002Fp>\n\n\u003Cp>Since declaration of the COVID-19 public health emergency,\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> a number of hand sanitizer products have been recalled due to quality issues ranging from substitution with other drug substances to subpotency.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> The Agency has reached out to registered OTC drug firms with hand sanitizers included in their product listing to assess the overall quality of the drugs registered as manufactured by these firms. Because your OTC drug firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.\u003C\u002Fp>\n\n\u003Cp>We note that, while your firm is registered with the FDA as a manufacturer of OTC drug products, your website indicates your firm is also involved in pipeline operations and fracturing, also known as fracking. Fracking operations typically involve multiple chemicals that could be harmful to patients if they were to contaminate drugs, such as your hand sanitizers.\u003C\u002Fp>\n\n\u003Cp>Respond to this letter within 48 hours to confirm or update your registration and\u002For drug listing status and indicate whether you will respond to the request for records and other information. If you are no longer manufacturing drugs, delist all the drugs previously listed with FDA, using the last lot expiration date as the marketing end date of the product, and deregister your facility accordingly.\u003C\u002Fp>\n\n\u003Cp>The Agency may conduct an inspection to verify information provided and\u002For to evaluate the compliance of your manufacturing operations.\u003C\u002Fp>\n\n\u003Cp>Continued non-response regarding questions of the quality assurance of the drugs manufactured at your facility may lead to inclusion on the Agency’s list of hand sanitizers consumers should not use, at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>You may provide additional information for our consideration as we continue to assess your activities and practices.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Identify your response with FEI 3016866715 and ATTN: Marisa Heayn.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research, FDA\u003C\u002Fp>\n\n\u003Cp>__________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The HHS Declaration of a Public Health Emergency is available at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Travis Pitcock\n\nRecipient Title\n\nChief Executive Officer\n\nTrue Chemical Solutions, LLC\n\n6215 W. County Road 112\n\nMidland, TX 79706\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-21-60\n\nSeptember 29, 2021\n\nDear Mr. Pitcock:\n\nYour firm is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products; specifically, products listed include HAPPY HANDS Hand Sanitizer Topical Gel with Moisturizing Solution. On November 10, 2020, the FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file. This request went unanswered, as did numerous telephone calls from the Agency regarding this matter, so the Agency sent a follow-up written request for such records and other information by certified return-receipt mail on May 4, 2021. Delivery was confirmed by your signature, but you failed to respond to these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request and follow-up communication included a sufficient and clear description of the records sought.\n\nIt is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a).\n\nSince declaration of the COVID-19 public health emergency,1 a number of hand sanitizer products have been recalled due to quality issues ranging from substitution with other drug substances to subpotency.2 The Agency has reached out to registered OTC drug firms with hand sanitizers included in their product listing to assess the overall quality of the drugs registered as manufactured by these firms. Because your OTC drug firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.\n\nWe note that, while your firm is registered with the FDA as a manufacturer of OTC drug products, your website indicates your firm is also involved in pipeline operations and fracturing, also known as fracking. Fracking operations typically involve multiple chemicals that could be harmful to patients if they were to contaminate drugs, such as your hand sanitizers.\n\nRespond to this letter within 48 hours to confirm or update your registration and\u002For drug listing status and indicate whether you will respond to the request for records and other information. If you are no longer manufacturing drugs, delist all the drugs previously listed with FDA, using the last lot expiration date as the marketing end date of the product, and deregister your facility accordingly.\n\nThe Agency may conduct an inspection to verify information provided and\u002For to evaluate the compliance of your manufacturing operations.\n\nContinued non-response regarding questions of the quality assurance of the drugs manufactured at your facility may lead to inclusion on the Agency’s list of hand sanitizers consumers should not use, at: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use.\n\nYou may provide additional information for our consideration as we continue to assess your activities and practices.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\n\nIdentify your response with FEI 3016866715 and ATTN: Marisa Heayn.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research, FDA\n\n__________________________\n\n1 The HHS Declaration of a Public Health Emergency is available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002F2019-nCoV.aspx.\n\n2 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance.","True Chemical Solutions, LLC","true-chemical-solutions-llc-616672-09292021","2026-08-18T06:42:29.386127+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftrue-chemical-solutions-llc-616672-09292021","2026-10-26T08:10:15.483298+00:00","Warning Letter","Issued","2021-10-05","616672","Drugs","Mr. Travis Pitcock","2026-08-20T02:35:09.615+00:00","VIA UPS","2021-09-29",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":52,"medical_device_id":19,"response_letter_date":19},544,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2025-10-07T04:00:00Z\">10\u002F07\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-26T04:00:00Z\">09\u002F26\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftechnological-medical-advancements-llc-712715-09262025\">Technological Medical Advancements LLC\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Bruce R. Coren, DVM, MS\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Technological Medical Advancements LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1601 Belvedere Rd Ste E-180\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>West Palm Beach\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33406-1541\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:bcoren@diowavelaser.com\"> bcoren@diowavelaser.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS # 712715\u003C\u002Fp>\u003Cp>September 26, 2025\u003C\u002Fp>\u003Cp>Dear Dr. Coren:&nbsp;\u003C\u002Fp>\u003Cp>During an inspection of your firm located in West Palm Beach, Florida from April 9, 2025, through April 21, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Diowave 250 WLS and Diowave 100 WLS laser system. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has reviewed the information collected during the April 2025 inspection and information on your firm’s website at www.diowavelaser.com (last accessed on July 1, 2025). FDA has reviewed the Physician Brochure (TMA, Physician Brochure, February 2024), AI Instructions for Use (TMA, Diowave 100 WLS &amp; Diowave 250 WLS, IMPOS-AI User Instructions, Undated, 1 page.pdf ), Diowave Life Without Pain Brochure (Diowave Laser Treatment Center, Imagine Life Without Pain Brochure), and an Operating Manual (TWA, Diowave Stealth Micro-Pulse Laser System Operating Manual Version 2024-5), and has determined that the Diowave 100 WLS and Diowave 250 WLS devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B) because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The Diowave 100 WLS and Diowave 250 WLS devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. §360(k). Specifically, the Diowave 100 WLS and the Diowave 250 WLS are in violation of the Act for the reasons discussed below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Technological Characteristics:\u003C\u002Fstrong> Devices classified under 21 CFR 890.5500 Infrared Lamp are devices intended for medical purposes that emits energy at infrared frequencies to provide topical heating and are exempt from premarket notification requirements unless they exceed the limitations on exemption at 21 CFR 890.9. However, there is evidence that the Diowave 250 WLS and Diowave 100 WLS operate using a different fundamental scientific technology than that generic type of device. Specifically, your firm’s Care Provider Brochure states that “\u003Cem>all heat during a stealth treatment is inhibited, allowing for deep penetration as there is no heat during treatment\u003C\u002Fem>.” Further, the Diowave 100 WLS and Diowave 250 WLS appear to utilize stealth micro-pulse laser technology, which does not provide topical heating. For example, your distribution includes materials with claims such as:\u003C\u002Fp>\u003Cp>\u003Cem>o\u003C\u002Fem>&nbsp;\u003Cem> “Diowave is pleased to reveal the Stealth Micro-Pulsed Laser System™. SMPLTallows you to hold a hand piece static over a focal pathology without heating tissue..”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“Our Stealth Micro-Pulse Technology allows care providers to treat various pathologies by Micro-Pulsing at appropriate power levels without introducing heat.”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“The Doctor can remove all heat from the laser beam allowing him to hold thelaser directly over the injury for an indefinite amount of time.”\u003C\u002Fem>\u003C\u002Fp>\u003Cp>As shown by the evidence, the Diowave 100 WLS and Diowave 250 WLS devices do not provide topical heating. Instead, they use a different fundamental scientific technology. Therefore, the premarket notification requirements apply.\u003C\u002Fp>\u003Cp>\u003Cstrong>Intended Use:\u003C\u002Fstrong>\u003Cbr>Generic devices classified under 21 CFR 890.5500 emit energy at infrared frequencies (approximately 700 to 50,000 nanometers) to provide topical heating and are intended for medical purposes including, but not limited to, temporary increase in local blood circulation and temporary relief of: muscle spasms, minor joint pain and stiffness, minor muscle pain and stiffness, and minor arthritis pain. Devices classified under 21 CFR 890.5500 are exempt from premarket notification unless they exceed the limitations on exemption at 21 CFR 890.9(a). However, there is evidence that the Diowave 250 WLS and Diowave 100 WLS are intended for uses that are different from the intended use of the type of devices classified under 21 CFR 890.5500 Infrared Lamp. For example, your distribution of the Diowave 100 WLS and Diowave 250 WLS devices includes the following claims:\u003C\u002Fp>\u003Cp>\u003Cem>o &nbsp;“a painless, non-surgical, and side-effective way to treat conditions previously refractive to traditional medical care”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“treatment of various pathologies, including those refractive to traditional therapy”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“Because laser therapy is the only treatment in medicine that actually heals living tissue, most conditions respond favorably to repeated laser therapy treatments. It has been proven to deliver results when all other forms of insurance-based medicine have failed.”&nbsp;&nbsp;\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“This technology has shown great promise in healing conditions which are refractive or non-responsive to all other forms of treatment and surgery, including HPLT [High Power Laser Therapy]”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“peripheral neuropathy” case study: “An 80-year-old male with advance circulatory disease in his lower extremities presents with numbness in his feet and toes. He cannot drive because he cannot feel his feet…by the end of 12 visits, his proprioception to the bottom of his feet returned”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“Summation of Various Main Treatment Indications for Diowave:…abdominalpain, pelvic pain, wound care”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“Difficult to treat pathologies that are adequately treated by Diowave: post-surgical pain, implantable device pocket pain, surgically fused areas in which insurance will not cover further treatment, areas that do not respond well to nerve blocks or joint injections, “disc pathology, wounds refractory to conventional medical treatment, after regenerative medicine treatment: using laser to amplify effects of regenerative medicine treatments by kickstarting the process.”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“results come from the laser’s ability to stimulate tissue growth and repair…results in accelerated wound healing with a dramatic decrease in…inflammation, and scar tissue formation”\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Further, we note that your firm has an existing clearance (K121363) under 21 CFR 890.5500 with the following indications:\u003C\u002Fp>\u003Cp>\u003Cem>“The Diowave Laser System is intended to emit energy in the infrared spectrum to provide topical heating for the purpose of elevating tissue temperature for temporary relief of minor muscle and joint pain, muscle spasm, pain and stiffness associated with minor arthritis, promoting relaxation of muscle tissue, and to temporarily increase local blood circulation.”\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm’s promotion of the device provides evidence that the device is intended for conditions beyond the indications for which it was cleared. Examples of these claims are included above. This constitutes a major change or modification in the intended use. Thus, a new premarket notification is required. Additionally, your firm’s promotion of the device provides evidence that your firm made a technological change to the device that could significantly affect the safety or effectiveness of the device. Examples of these claims are included above. This change is a significant change or modification for which a new premarket notification is required.\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fd efault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Our office requests that Technological Medical Advancements LLC cease any activities that result in the misbranding or adulteration of the Diowave 100 WLS and Diowave 250 WLS devices, such as the commercial distribution of the device, for the uses discussed above.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. Your firm’s response dated May 23, 2025, to the Form FDA 483 (FDA 483) was not received within fifteen business days of issuance of the FDA 483 however we performed a review of your response. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish procedures to ensure that all purchased or otherwise received products and services conform to specified requirements, as required by 21 CFR 820.50.Specifically,\u003C\u002Fp>\u003Cp>A. Your firm has failed to perform supplier evaluations as required by Purchasing Control Standard Operating Procedure, TMAQSP007, Revision 2.0. These include evaluations for critical suppliers, comprised of your contract manufacturer and designer \u003Cstrong>(b)(4)\u003C\u002Fstrong> and your contract service firm \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as required by Section 3 of your procedure. Additionally, no \u003Cstrong>(b)(4)\u003C\u002Fstrong> evaluations were conducted for any suppliers despite procedural requirements, and no justification was provided for not performing them.\u003C\u002Fp>\u003Cp>B. Your firm failed to maintain supplier agreements as required by your Supplier Evaluation and Monitoring Standard Operating Procedure, TMA_QSP_023. For example, section 6.1.2 of your procedure states that “a Quality Agreement\u002FCritical Supplier Quality Agreement is drafted and signed between both parties.” However, your firm has unsigned agreements with your contract manufacturer, including both the Critical Supplier Quality Agreement and Software Agreement. During the inspection, your contract manufacturer was unable to provide required design control records for review.\u003C\u002Fp>\u003Cp>C. The inspection noted that your firm failed to have adequate purchasing controls and supplier oversight of your firm’s contract manufacturer, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, responsible for design controls. Your firm's inability to retrieve basic design control records from your contract designer\u002Fmanufacturer during the FDA inspection, despite claims that these documents existed, demonstrates inadequate oversight of critical supplier activities. For example:\u003C\u002Fp>\u003Cp>i. &nbsp;Your firm could not provide the Design History File (DHF) records for the Diowave 250 WLS and Diowave 100 WLS medical devices. The inspection found no evidence of essential design control records including design planning, design inputs, design outputs, design reviews, design verification, design validation, design change or design transfer, representing a comprehensive failure to maintain adequate design control records as required by FDA regulations. As such, FDA is concerned that the medical devices will not consistently meet intended use and safety requirements, that design changes are not properly controlled and documented, and that the finished device design may not meet user needs and intended use.\u003C\u002Fp>\u003Cp>ii. &nbsp;The design risk management files for the Diowave 250 WLS and Diowave 100WLS laser device were not available for review. No records were available toreview by FDA investigators for design risk analysis despite your proceduralrequirements in section 3.4 of Risk Management Standard Operating Procedure,TMAQSP043, Revision 1.0, to incorporate risk analysis into your firm’s DesignReview. No risk assessment was available for review for the power increase from \u003Cstrong>(b)(4)\u003C\u002Fstrong>W to \u003Cstrong>(b)(4)\u003C\u002Fstrong>W. No evaluation on the potential need to submit a new premarket application was performed.\u003C\u002Fp>\u003Cp>iii. &nbsp;Your firm’s Supplier Evaluation and Monitoring Standard OperatingTMA_QSP_023, Revision 1 states in section 6.2 that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>. ”There have been significant modifications to your devices without notification from critical supplier or oversight and approval of changes by your firm. This includes the review of design control records such as design verification and design validation to include risk analysis. For example, design control records for changes to software (\u003Cstrong>(b)(4)\u003C\u002Fstrong> for 250 WLS, \u003Cstrong>(b)(4)\u003C\u002Fstrong> for 100 WLS), as well as an identified power increase for the Diowave laser systems from \u003Cstrong>(b)(4)\u003C\u002Fstrong>W to \u003Cstrong>(b)(4)\u003C\u002Fstrong>W were not available for review during the inspection.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Your firm’s response does not address deficiencies with the purchasing controls and oversight of the design control activities delegated to your contract manufacturer. In addition, while your firm provided some design control records from your contract manufacturer, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you did not provide records that include the changes to the Diowave Laser System 100 WLS\u002F250 WLS or design inputs, and therefore, we are unable determine if the device design outputs meet the design inputs. The design output records provided are missing complete device specifications, manufacturing specifications, software design specifications and labeling specifications. The design review documents are missing design reviews for all phases of the device design plan. There is no design change control for design changes previously described. The design transfer document does not include all required design transfer activities and any manufacturing process validations performed. Following our review of your response, you have not addressed the deficiencies in your firm’s design control subsystem and the requirement for a complete design history file (DHF) for your medical devices.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit and to maintain complaint files, as required by 21CFR 820.198(a). For example:\u003C\u002Fp>\u003Cp>A. FDA investigators reviewed ten complaints from 2025 and identified comprehensive procedural failures for the receipt, review, and evaluation of complaints. Your firm failed to implement Customer Complaints procedure, TMAQSP003, Revision 3.0,and perform required procedural activities for all complaints reviewed, including complaint investigations, failure mode analysis, Management Representative approval, and completing all fields in the complaint forms.\u003C\u002Fp>\u003Cp>B. Your firm failed to handle all complaints in a timely manner. For example, your firm has not reviewed or evaluated \u003Cstrong>(b)(4)\u003C\u002Fstrong> servicing records from the third-party supplier as specified by your procedure TMA_QSP_009 Servicing, Rev 2.0, so that the Management Representative can determine if they meet the definition of a complaint so that they can be investigated as necessary.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address this inspectional observation, and therefore is missing a corrective action plan, time frames for implementation, and documentation of activities performed to correct the underlying deficiency.\u003C\u002Fp>\u003Cp>3. Your firm has failed to adequately establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm has not adequately established CAPA Procedure, TMAQSP012, Revision 1.0. For example:\u003C\u002Fp>\u003Cp>A. Your procedure lacks requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems.\u003C\u002Fp>\u003Cp>B. Your firm has not implemented Section 3.2 of the CAPA procedure to identify actions needed to correct and prevent the recurrence of any non-conformity. For example, your firm has not opened any corrective and preventive actions, as required by your procedure, after it has been cited with the following:\u003C\u002Fp>\u003Cp>&nbsp; i. Fourteen inspectional observations from an FDA inspection conducted from August 4, 2021, to September 9, 2021;\u003Cbr>&nbsp; ii. Thirteen observations, along with seven verbal observations, from an FDA inspection conducted from February 19, 2020 to February 24, 2020;\u003Cbr>&nbsp; iii. Twelve violations cited in a letter sent to your firm on June 8, 2020, by FDA.\u003C\u002Fp>\u003Cp>This FDA inspection, along with previous FDA inspections, have identified repeat systemic deficiencies of your firm’s inability to identify actions to correct and prevent the recurrence of quality problems.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\u003C\u002Fp>\u003Cp>4. Your firm has failed to establish and maintain adequate procedures for quality audits, as required by 21 CFR 820.22. Specifically, your firm did not conduct quality audits in 2023and 2024 as required by your Internal Audit Standard Operating Procedure, TMAQSP004,Revision 1.0. As of the date of the inspection, no quality audit has been conducted in 2025.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\u003C\u002Fp>\u003Cp>5. Your firm has failed to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). Specifically, your firm does not have a procedure for addressing nonconforming products or materials. When the FDA investigator asked about procedures for nonconforming products or materials, you stated that such procedures did not exist. Without procedures to define nonconformance criteria and disposition processes, your firm cannot effectively identify or manage quality issues that may arise during manufacturing, incoming inspection, acceptance testing activities or as part of post-market surveillance activities.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\u003C\u002Fp>\u003Cp>6. Your firm has failed to adequately establish and maintain procedures for management review, as required by 21 CFR 820.20(c). Specifically, your firm did not follow Management Review Standard Operating Procedure, TMAQSP010, Revision 1.0, which requires periodic management review at least \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm did not conduct a management review in 2024, thereby failing to determine the effectiveness of your quality system. This inspection identified several inspectional observations and deficiencies that have gone uncorrected from the two previous FDA inspections or approximately 5 years.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unique Device Identifier Regulation (UDI) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the Diowave Pure Pulse Laser System devices do not bear such a UDI.\u003C\u002Fp>\u003Cp>Specifically, the labels for Diowave Pure Pulse Laser System devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of the device (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology on the label of the device (see 21 CFR 801.40(a)(2)).\u003C\u002Fp>\u003Cp>A follow-up inspection will be required to assure that corrections and\u002For corrective actions are adequate. Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Melissa Michurski, Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 712715” when replying. If you have any questions about the contents of this letter, please contact: Rafael Padilla at Rafael.Padilla@FDA.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Acting Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDr. Bruce R. Coren, DVM, MS\n\nRecipient Title\n\nChief Executive Officer\n\nTechnological Medical Advancements LLC\n\n1601 Belvedere Rd Ste E-180\n\nWest Palm Beach, FL 33406-1541\n\nUnited States\n\nbcoren@diowavelaser.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 712715\nSeptember 26, 2025\nDear Dr. Coren:\nDuring an inspection of your firm located in West Palm Beach, Florida from April 9, 2025, through April 21, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Diowave 250 WLS and Diowave 100 WLS laser system. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nUnapproved Device Violations\nFDA has reviewed the information collected during the April 2025 inspection and information on your firm’s website at www.diowavelaser.com (last accessed on July 1, 2025). FDA has reviewed the Physician Brochure (TMA, Physician Brochure, February 2024), AI Instructions for Use (TMA, Diowave 100 WLS & Diowave 250 WLS, IMPOS-AI User Instructions, Undated, 1 page.pdf ), Diowave Life Without Pain Brochure (Diowave Laser Treatment Center, Imagine Life Without Pain Brochure), and an Operating Manual (TWA, Diowave Stealth Micro-Pulse Laser System Operating Manual Version 2024-5), and has determined that the Diowave 100 WLS and Diowave 250 WLS devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B) because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The Diowave 100 WLS and Diowave 250 WLS devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. §360(k). Specifically, the Diowave 100 WLS and the Diowave 250 WLS are in violation of the Act for the reasons discussed below.\nTechnological Characteristics: Devices classified under 21 CFR 890.5500 Infrared Lamp are devices intended for medical purposes that emits energy at infrared frequencies to provide topical heating and are exempt from premarket notification requirements unless they exceed the limitations on exemption at 21 CFR 890.9. However, there is evidence that the Diowave 250 WLS and Diowave 100 WLS operate using a different fundamental scientific technology than that generic type of device. Specifically, your firm’s Care Provider Brochure states that “all heat during a stealth treatment is inhibited, allowing for deep penetration as there is no heat during treatment.” Further, the Diowave 100 WLS and Diowave 250 WLS appear to utilize stealth micro-pulse laser technology, which does not provide topical heating. For example, your distribution includes materials with claims such as:\no “Diowave is pleased to reveal the Stealth Micro-Pulsed Laser System™. SMPLTallows you to hold a hand piece static over a focal pathology without heating tissue..”\no “Our Stealth Micro-Pulse Technology allows care providers to treat various pathologies by Micro-Pulsing at appropriate power levels without introducing heat.”\no “The Doctor can remove all heat from the laser beam allowing him to hold thelaser directly over the injury for an indefinite amount of time.”\nAs shown by the evidence, the Diowave 100 WLS and Diowave 250 WLS devices do not provide topical heating. Instead, they use a different fundamental scientific technology. Therefore, the premarket notification requirements apply.\nIntended Use:\nGeneric devices classified under 21 CFR 890.5500 emit energy at infrared frequencies (approximately 700 to 50,000 nanometers) to provide topical heating and are intended for medical purposes including, but not limited to, temporary increase in local blood circulation and temporary relief of: muscle spasms, minor joint pain and stiffness, minor muscle pain and stiffness, and minor arthritis pain. Devices classified under 21 CFR 890.5500 are exempt from premarket notification unless they exceed the limitations on exemption at 21 CFR 890.9(a). However, there is evidence that the Diowave 250 WLS and Diowave 100 WLS are intended for uses that are different from the intended use of the type of devices classified under 21 CFR 890.5500 Infrared Lamp. For example, your distribution of the Diowave 100 WLS and Diowave 250 WLS devices includes the following claims:\no “a painless, non-surgical, and side-effective way to treat conditions previously refractive to traditional medical care”\no “treatment of various pathologies, including those refractive to traditional therapy”\no “Because laser therapy is the only treatment in medicine that actually heals living tissue, most conditions respond favorably to repeated laser therapy treatments. It has been proven to deliver results when all other forms of insurance-based medicine have failed.”\no “This technology has shown great promise in healing conditions which are refractive or non-responsive to all other forms of treatment and surgery, including HPLT [High Power Laser Therapy]”\no “peripheral neuropathy” case study: “An 80-year-old male with advance circulatory disease in his lower extremities presents with numbness in his feet and toes. He cannot drive because he cannot feel his feet…by the end of 12 visits, his proprioception to the bottom of his feet returned”\no “Summation of Various Main Treatment Indications for Diowave:…abdominalpain, pelvic pain, wound care”\no “Difficult to treat pathologies that are adequately treated by Diowave: post-surgical pain, implantable device pocket pain, surgically fused areas in which insurance will not cover further treatment, areas that do not respond well to nerve blocks or joint injections, “disc pathology, wounds refractory to conventional medical treatment, after regenerative medicine treatment: using laser to amplify effects of regenerative medicine treatments by kickstarting the process.”\no “results come from the laser’s ability to stimulate tissue growth and repair…results in accelerated wound healing with a dramatic decrease in…inflammation, and scar tissue formation”\nFurther, we note that your firm has an existing clearance (K121363) under 21 CFR 890.5500 with the following indications:\n“The Diowave Laser System is intended to emit energy in the infrared spectrum to provide topical heating for the purpose of elevating tissue temperature for temporary relief of minor muscle and joint pain, muscle spasm, pain and stiffness associated with minor arthritis, promoting relaxation of muscle tissue, and to temporarily increase local blood circulation.”\nYour firm’s promotion of the device provides evidence that the device is intended for conditions beyond the indications for which it was cleared. Examples of these claims are included above. This constitutes a major change or modification in the intended use. Thus, a new premarket notification is required. Additionally, your firm’s promotion of the device provides evidence that your firm made a technological change to the device that could significantly affect the safety or effectiveness of the device. Examples of these claims are included above. This change is a significant change or modification for which a new premarket notification is required.\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fd efault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nOur office requests that Technological Medical Advancements LLC cease any activities that result in the misbranding or adulteration of the Diowave 100 WLS and Diowave 250 WLS devices, such as the commercial distribution of the device, for the uses discussed above.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. Your firm’s response dated May 23, 2025, to the Form FDA 483 (FDA 483) was not received within fifteen business days of issuance of the FDA 483 however we performed a review of your response. These violations include, but are not limited to, the following:\n1. Failure to adequately establish procedures to ensure that all purchased or otherwise received products and services conform to specified requirements, as required by 21 CFR 820.50.Specifically,\nA. Your firm has failed to perform supplier evaluations as required by Purchasing Control Standard Operating Procedure, TMAQSP007, Revision 2.0. These include evaluations for critical suppliers, comprised of your contract manufacturer and designer (b)(4) and your contract service firm (b)(4), as required by Section 3 of your procedure. Additionally, no (b)(4) evaluations were conducted for any suppliers despite procedural requirements, and no justification was provided for not performing them.\nB. Your firm failed to maintain supplier agreements as required by your Supplier Evaluation and Monitoring Standard Operating Procedure, TMA_QSP_023. For example, section 6.1.2 of your procedure states that “a Quality Agreement\u002FCritical Supplier Quality Agreement is drafted and signed between both parties.” However, your firm has unsigned agreements with your contract manufacturer, including both the Critical Supplier Quality Agreement and Software Agreement. During the inspection, your contract manufacturer was unable to provide required design control records for review.\nC. The inspection noted that your firm failed to have adequate purchasing controls and supplier oversight of your firm’s contract manufacturer, (b)(4), responsible for design controls. Your firm's inability to retrieve basic design control records from your contract designer\u002Fmanufacturer during the FDA inspection, despite claims that these documents existed, demonstrates inadequate oversight of critical supplier activities. For example:\ni. Your firm could not provide the Design History File (DHF) records for the Diowave 250 WLS and Diowave 100 WLS medical devices. The inspection found no evidence of essential design control records including design planning, design inputs, design outputs, design reviews, design verification, design validation, design change or design transfer, representing a comprehensive failure to maintain adequate design control records as required by FDA regulations. As such, FDA is concerned that the medical devices will not consistently meet intended use and safety requirements, that design changes are not properly controlled and documented, and that the finished device design may not meet user needs and intended use.\nii. The design risk management files for the Diowave 250 WLS and Diowave 100WLS laser device were not available for review. No records were available toreview by FDA investigators for design risk analysis despite your proceduralrequirements in section 3.4 of Risk Management Standard Operating Procedure,TMAQSP043, Revision 1.0, to incorporate risk analysis into your firm’s DesignReview. No risk assessment was available for review for the power increase from (b)(4)W to (b)(4)W. No evaluation on the potential need to submit a new premarket application was performed.\niii. Your firm’s Supplier Evaluation and Monitoring Standard OperatingTMA_QSP_023, Revision 1 states in section 6.2 that “(b)(4). ”There have been significant modifications to your devices without notification from critical supplier or oversight and approval of changes by your firm. This includes the review of design control records such as design verification and design validation to include risk analysis. For example, design control records for changes to software ((b)(4) for 250 WLS, (b)(4) for 100 WLS), as well as an identified power increase for the Diowave laser systems from (b)(4)W to (b)(4)W were not available for review during the inspection.\nWe reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Your firm’s response does not address deficiencies with the purchasing controls and oversight of the design control activities delegated to your contract manufacturer. In addition, while your firm provided some design control records from your contract manufacturer, (b)(4), you did not provide records that include the changes to the Diowave Laser System 100 WLS\u002F250 WLS or design inputs, and therefore, we are unable determine if the device design outputs meet the design inputs. The design output records provided are missing complete device specifications, manufacturing specifications, software design specifications and labeling specifications. The design review documents are missing design reviews for all phases of the device design plan. There is no design change control for design changes previously described. The design transfer document does not include all required design transfer activities and any manufacturing process validations performed. Following our review of your response, you have not addressed the deficiencies in your firm’s design control subsystem and the requirement for a complete design history file (DHF) for your medical devices.\n2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit and to maintain complaint files, as required by 21CFR 820.198(a). For example:\nA. FDA investigators reviewed ten complaints from 2025 and identified comprehensive procedural failures for the receipt, review, and evaluation of complaints. Your firm failed to implement Customer Complaints procedure, TMAQSP003, Revision 3.0,and perform required procedural activities for all complaints reviewed, including complaint investigations, failure mode analysis, Management Representative approval, and completing all fields in the complaint forms.\nB. Your firm failed to handle all complaints in a timely manner. For example, your firm has not reviewed or evaluated (b)(4) servicing records from the third-party supplier as specified by your procedure TMA_QSP_009 Servicing, Rev 2.0, so that the Management Representative can determine if they meet the definition of a complaint so that they can be investigated as necessary.\nWe reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address this inspectional observation, and therefore is missing a corrective action plan, time frames for implementation, and documentation of activities performed to correct the underlying deficiency.\n3. Your firm has failed to adequately establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm has not adequately established CAPA Procedure, TMAQSP012, Revision 1.0. For example:\nA. Your procedure lacks requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems.\nB. Your firm has not implemented Section 3.2 of the CAPA procedure to identify actions needed to correct and prevent the recurrence of any non-conformity. For example, your firm has not opened any corrective and preventive actions, as required by your procedure, after it has been cited with the following:\ni. Fourteen inspectional observations from an FDA inspection conducted from August 4, 2021, to September 9, 2021;\nii. Thirteen observations, along with seven verbal observations, from an FDA inspection conducted from February 19, 2020 to February 24, 2020;\niii. Twelve violations cited in a letter sent to your firm on June 8, 2020, by FDA.\nThis FDA inspection, along with previous FDA inspections, have identified repeat systemic deficiencies of your firm’s inability to identify actions to correct and prevent the recurrence of quality problems.\nWe reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\n4. Your firm has failed to establish and maintain adequate procedures for quality audits, as required by 21 CFR 820.22. Specifically, your firm did not conduct quality audits in 2023and 2024 as required by your Internal Audit Standard Operating Procedure, TMAQSP004,Revision 1.0. As of the date of the inspection, no quality audit has been conducted in 2025.\nWe reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\n5. Your firm has failed to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). Specifically, your firm does not have a procedure for addressing nonconforming products or materials. When the FDA investigator asked about procedures for nonconforming products or materials, you stated that such procedures did not exist. Without procedures to define nonconformance criteria and disposition processes, your firm cannot effectively identify or manage quality issues that may arise during manufacturing, incoming inspection, acceptance testing activities or as part of post-market surveillance activities.\nWe reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\n6. Your firm has failed to adequately establish and maintain procedures for management review, as required by 21 CFR 820.20(c). Specifically, your firm did not follow Management Review Standard Operating Procedure, TMAQSP010, Revision 1.0, which requires periodic management review at least (b)(4). Your firm did not conduct a management review in 2024, thereby failing to determine the effectiveness of your quality system. This inspection identified several inspectional observations and deficiencies that have gone uncorrected from the two previous FDA inspections or approximately 5 years.\nWe reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\nUnique Device Identifier Regulation (UDI) Violations\nThe inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the Diowave Pure Pulse Laser System devices do not bear such a UDI.\nSpecifically, the labels for Diowave Pure Pulse Laser System devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of the device (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology on the label of the device (see 21 CFR 801.40(a)(2)).\nA follow-up inspection will be required to assure that corrections and\u002For corrective actions are adequate. Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Melissa Michurski, Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 712715” when replying. If you have any questions about the contents of this letter, please contact: Rafael Padilla at Rafael.Padilla@FDA.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nActing Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Technological Medical Advancements LLC","technological-medical-advancements-llc-712715-09262025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftechnological-medical-advancements-llc-712715-09262025","2026-10-26T08:10:10.367898+00:00","2025-10-07","712715","Medical Devices","Dr. Bruce R. Coren, DVM, MS","2026-08-19T16:15:16.641+00:00","VIA Electronic Mail","2025-09-26",{"id":54,"raw":55,"subject":60,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":19,"letter_url":66,"updated_at":67,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":69,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":70,"body_fetched_at":71,"delivery_method":72,"recipient_title":19,"reference_number":19,"action_taken_date":73,"medical_device_id":19,"response_letter_date":19},1152,[56,57,58,37,59,13,13,13],"\u003Ctime datetime=\"2024-11-26T14:20:00Z\">11\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-10-11T04:00:00Z\">10\u002F11\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadept-medical-ltd-692226-10112024\">Adept Medical Ltd. \u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Murray Fenton\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder, CEO and Guiding Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Adept Medical Ltd. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2-6 Mc Donald Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Morningside\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Auckland\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>New Zealand\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 11, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Fenton:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Auckland, New Zealand on May 13, 2024, through May 16, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Tympanostomy Tubes \"NeoZoline Ventilation Tubes\". Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. §351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Ms. Yi Huang, Quality and Regulatory Manager dated June 13, 2024, concerning our investigator's observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures for acceptance activities, which include inspections, tests, or other verification activities, as required by 21 CFR 820.80(a).\u003C\u002Fp>\n\n\u003Cp>For example:\u003C\u002Fp>\n\n\u003Cp>1) Your firm's current incoming inspection and acceptance procedure for Biological Indicator \u003Cstrong>(b)(4)\u003C\u002Fstrong> (BI) is not adequately established. This inadequacy could compromise the sterilization process, potentially affecting the safety and effectiveness of the NeoZoline V ntilation Tubes. Your firm discards the Certificate of Conformance provided by&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> with each BI batch, which was requested by the FDA investigator during the inspection. It appears that your firm failed to retain critical documents such as the reconciliation sheet, production batch record, or \u003Cstrong>(b)(4)\u003C\u002Fstrong> Certification of Conformance, which are required under your own WI22 \"Production QC and Release Product Register,\" specifically section 2.3, to demonstrate that the product was successfully sterilized. The inspection revealed that your firm does not perform BI Population verification tests on the received BI batches to ensure that the population has not changed during shipping or storage. This is a critical step is necessary to provide a high degree of assurance that the BIs are viable to support verification that finished product is successfully sterilized through the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Sterilization process. Additionally, the inspection revealed that critical information such as the batch number and expiration date of the BI used in the sterile load is not documented on the post-sterilization B1 Test Reports, which are used as part of the finished device acceptance and release process.\u003C\u002Fp>\n\n\u003Cp>2) Your firm's incoming inspection and acceptance procedure for Sterile Potties (M1421, M1422) used for storing ultrasound cleaned NeoZoline Ventilation Tubes is not adequately established. The inspection revealed that your firm accepts incoming sterile pottle lots without a Certificate of Sterilization from the supplier. \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm stated that no additional testing or verification is performed to ensure the sterility of the incoming potties.&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on June 1, 2024. Your firm concluded that a risk analysis of the specific observation indicates no risk to end users for products currently in distribution and manufacturing. That conclusion is based on the following factors:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> Biological Indicator is an off the shelf product from supplier where \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;has claimed compliance with ISO 11138-1:2017 and ISO 11138-2:2017.\u003C\u002Fli>\n\t\u003Cli>The BI is packaged in a foil pouch designed to protect the product from humidity excursions.\u003C\u002Fli>\n\t\u003Cli>The potties are used to store non-sterile Ventilation Tubes hence the sterility of the pottle is not a requirement.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, your firm has outlined a plan with the following actions to be completed by December 1, 2024, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on your firm's response there is an ambiguity in the definition of the term `pottle' and whether it is required to be sterile or not. \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>your firm's response states that there is no risk for the stenle products manufactured at your facility because the BIs that they use conform to ISO 11138-1:2017 and ISO 11138-2:2017, and that they are in their sterile packaging until they are needed. However, the inspection demonstrated that your firm does not do any testing to verify that the BIs purchased for the purpose of demonstrating that terminal sterilization is achieved, are actually viable when they are used. Additionally, the inspection revealed that they do not capture key data such as BI batch number and expiration date, and thus if a BI falsely indicated that a sterilization was successful, there is no mechanism by which your firm can trace the lots of sterile products back to a failed BI.\u003C\u002Fp>\n\n\u003Cp>Additionally, your firm did not include documentation or evidence of the corrections or corrective actions because they are in progress and have not been completed. Additionally, given the observations described above, your firm has not provided a commitment to conduct a retrospective assessment of all finished devices whose sterilization was verified using Biological Indicator \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>to determine whether sterility was compromised.\u003C\u002Fp>\n\n\u003Cp>2. Failure to ensure that where the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a). For example:\u003C\u002Fp>\n\n\u003Cp>1) Your firm's ultrasonic cleaning process using the&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Cleaner&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>is not adequately validated according to your firm's Manufacturing Process&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;\u003C\u002Fstrong>During the inspection, FDA's investigator revealed that the ultrasonic cleaning process was not adequately validated because critical details—such as the description of the NeoZoline Ventilation Tube (including part number, size, and shape), the number of validation batches (runs), validation batch size, and sample size used—were not documented.\u003C\u002Fp>\n\n\u003Cp>2) During the inspection, your firm stated that it had not validated the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>process for the NeoZoline Ventilation Tube&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm&nbsp;stated that the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.&nbsp; Adept Medical also confirmed during the inspection that&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;had not validated the NeoZoline Ventilation Tube&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;and that prior to Spring 2023,&nbsp;\u003Cstrong>(b)(4) \u003C\u002Fstrong>the\u003Cstrong>&nbsp;\u003C\u002Fstrong>NeoZoline Ventilation Tube \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>who also did not have a&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> NeoZoline Ventilation Tube.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates its Initial Action was completed on June 1, 2024. Your firm concluded that there is no risk to end users for products currently in supply and with distributors, based on the following factors:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>There is an existing validated sterilization process indicating a sterility assurance level of \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Annual bioburden results of pre-cleaned devices have bioburden levels below&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU.\u003C\u002Fli>\n\t\u003Cli>Current validation data, although not well documented in its sample selection and setting, still indicated the current setting provided adequate bioburden results, well within the capability of the sterilization process.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Additionally, your firm has outlined a plan to be completed by June 1, 2025, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>However, your firm has not provided any evidence to substantiate your claims that the&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>sterility assurance level or the bioburden limits below \u003Cstrong>(b)(4)\u003C\u002Fstrong> CFU were consistently achievable. The inspection raised concerns about your firm sterilization process, as discussed in the above section regarding compliance with 21 CFR 820.80(a). It is noteworthy that FDA requested validation documents for the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Cleaner during the May 2024 inspection and did not receive any documentation to indicate that this process was validated.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100. For example:\u003C\u002Fp>\n\n\u003Cp>Your firm's Corrective and Preventive Action (CAPA) procedure (M05-03) fails to ensure that:\u003C\u002Fp>\n\n\u003Cp>1) The quality data is adequately analyzed to identify potential and existing causes of nonconformances or other quality issues. Your firm stated to the FDA investigator that, although data is analyzed, they do not evaluate the results to determine whether any corrective or preventive actions are necessary, as required by 21 CFR 820.100(a)(3).\u003C\u002Fp>\n\n\u003Cp>2) Your firm failed to adequately verify the effectiveness of corrective actions for several CAPAs before closing them. Specifically, CAPAs CA-459, CA-438, and CA-437 were closed after implementing corrective actions, but your firm did not verify the effectiveness of these actions, as required by 21 CFR 820.100(a)(4).\u003C\u002Fp>\n\n\u003Cp>3) CA-429 was closed on February 16, 2023; at the time of the inspection, your firm stated that they had not started any of the corrective actions identified in the CAPA. As a result of the discussion during the inspection, your firm volunteered to mark the CAPA as 'open,' so that the corrective actions could be implemented.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that although procedure&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>the procedure did not instruct how to this data should be analyzed, and what subsequent actions should be taken once the data analysis is complete. However, your firm's procedure&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm has outlined the following plan to be completed by April 1, 2025, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>However, your firm's response does not identify conducting a retrospective analysis for all past CAPAs, to determine the impact of the lack of data analysis, and whether the appropriate corrective and\u002For preventive action was taken to address each CAPA's root cause. Additionally, your firm did not identify what actions it would take to address the lack of implementation of identified corrective actions and whether that issue is a systemic problem.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product; and failure to ensure that the evaluation includes a determination of the need for an investigation, as required by 21 CFR 820.90(a). For example:\u003C\u002Fp>\n\n\u003Cp>The FDA investigator reviewed six NC records related to your firm's NeoZoline Ventilation Tubes. All six NC records were closed (NC-2516, NC-2767, NC-2641, NC-2640, NC-2738, NC-2523), but showed the following deficiencies in documentation:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The NC records did not adequately document the evaluation of the identified nonconformities.\u003C\u002Fli>\n\t\u003Cli>The rationale for not conducting related investigations was inadequately documented in all six NC records.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your firm explained that incoming NeoZoline Ventilation Tubes \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>are not inspected upon arrival.&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;\u003C\u002Fstrong>Your firm further stated that they \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;\u003C\u002Fstrong>This target achievement was cited as the reason for not taking further action.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that there is no risk to end users for products currently in supply and with distributors. That conclusion is based on postmarket surveillance data, which shows no product safety or performance complaints since the product's launch. However, a lack of documented safety signals does not ensure that nonconforming product was controlled and not introduced into commerce.\u003C\u002Fp>\n\n\u003Cp>Additionally, your firm has outlined a plan to be completed by April 1, 2025, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>However, your firm did not include documentation to demonstrate that it has evaluated or will evaluate all past non-conformances against your new procedure to determine whether additional corrective action was required to address the non-conformances identified in your NC Records.\u003C\u002Fp>\n\n\u003Cp>5. Failure to define the type and extent of control to be exercised over the product, services, suppliers, contractors, and consultants, based on the evaluation results, as required by 21 CFR 820.50(a)(2). For example:\u003C\u002Fp>\n\n\u003Cp>During the inspection, your firm was asked whether the \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the NeoZoline ventilation tubes was validated&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm stated you have no knowledge or documentation regarding&nbsp;whether the&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>for the NeoZoline Ventilation Tubes had been properly&nbsp;validated.&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Adept Medical learned the&nbsp;\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>Adept Medical received \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;units of NeoZoline Ventilation Tubes in various types from&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;between June 2023 and November 2023. They released \u003Cstrong>(b)(4) \u003C\u002Fstrong>units\u003Cstrong>&nbsp;\u003C\u002Fstrong>(\u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>boxes) of the NeoZoline Ventilation Tubes to the United States. Prior to June 2023, all NeoZoline Ventilation Tubes were \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;&nbsp;\u003C\u002Fstrong>Adept has failed to ensure that the conditions of the supplier agreement were adhered to by your supplier.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that there is no risk to the end users for products currently in supply and with distributors, based on the following considerations:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>The post-market periodic safety update report (PSUR) on Ventilation Tubes supplied by \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>indicated no adverse events.\u003C\u002Fli>\n\t\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fli>\n\t\u003Cli>Post market surveillance data indicated we have had no product safety or performance complaints since product launch.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>However, a lack of adverse events in post market safety signals does not provide assurance that the device meets its design specifications, in light of the fact that, Adept Medical was unaware that your supplier \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;the NeoZoline Ventilation Tube \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>did not have any documentation that the \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>device was validated.\u003C\u002Fp>\n\n\u003Cp>Additionally, your firm has outlined a plan to be completed by June 1, 2025, which includes the following actions:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>However, based on your firm's response, it is unclear how you intend to evaluate suppliers' compliance with 21 CFR Part 820, the Quality System Regulation.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that the NeoZoline Ventilation Tubes are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PM_A) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, in that your firm did not notify FDA regarding a significant change or modification in the device that could significantly affect the safety or effectiveness of the device, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 C.F.R. 807.81 (a)(3)(i).\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm has modified the NeoZoline Ventilation Tubes cleared under K061058. The modification involves the use of a \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;which was not cleared in the original submission and is a change that could significantly affect the safety or effectiveness of the device. This modification necessitates a comprehensive risk assessment to ensure the device remains safe and effective. A new biocompatibility evaluation is required to determine if \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003Cstrong>&nbsp;\u003C\u002Fstrong>Any \u003Cstrong>(b)(4)\u003C\u002Fstrong> may affect how the device can be safely and effectively sterilized. Thus, your sterilization processes must be validated for the&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure that it can be properly sterilized without&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> becoming unsafe. The change in \u003Cstrong>(b)(4)\u003C\u002Fstrong> may alter the device's performance or specifications, so a thorough re-evaluation is necessary to ensure it still meets all necessary standards and functions as intended. Due to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> modification and its potential impact on the device's safety and performance, a new 510(k) submission is required before marketing the modified device in the United States.\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fd efault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm's response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #692226 when replying. If you have any questions about the contents of this letter, please contact: Shu-Chen Peng, Ph.D. at 301-796-6481.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Malvina B. Eydelman, M.D.\u003Cbr>\nDirector\u003Cbr>\nOHT1: Office of Ophthalmic, Anesthesia,\u003Cbr>\nRespiratory, ENT and Dental Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\n\u003Cstrong>(b)(4)\u003C\u002Fstrong>, Registrar Corp.,\u003Cbr>\n144 Research Drive,\u003Cbr>\nHampton, Virginia,\u003Cbr>\nUSA 23666\u003Cbr>\nPhone: Tel: 1-757-224-0177, Ext.&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cbr>\nEmail:\u003Cstrong>(b)(4)\u003C\u002Fstrong>@registrarcorp.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Murray Fenton\n\nRecipient Title\n\nFounder, CEO and Guiding Director\n\nAdept Medical Ltd.\n\n2-6 Mc Donald Street\n\nMorningside\n\nAuckland\n\nNew Zealand\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nOctober 11, 2024\n\nDear Mr. Fenton:\n\nDuring an inspection of your firm located in Auckland, New Zealand on May 13, 2024, through May 16, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures Tympanostomy Tubes \"NeoZoline Ventilation Tubes\". Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. §351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from Ms. Yi Huang, Quality and Regulatory Manager dated June 13, 2024, concerning our investigator's observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures for acceptance activities, which include inspections, tests, or other verification activities, as required by 21 CFR 820.80(a).\n\nFor example:\n\n1) Your firm's current incoming inspection and acceptance procedure for Biological Indicator (b)(4) (BI) is not adequately established. This inadequacy could compromise the sterilization process, potentially affecting the safety and effectiveness of the NeoZoline V ntilation Tubes. Your firm discards the Certificate of Conformance provided by (b)(4) with each BI batch, which was requested by the FDA investigator during the inspection. It appears that your firm failed to retain critical documents such as the reconciliation sheet, production batch record, or (b)(4) Certification of Conformance, which are required under your own WI22 \"Production QC and Release Product Register,\" specifically section 2.3, to demonstrate that the product was successfully sterilized. The inspection revealed that your firm does not perform BI Population verification tests on the received BI batches to ensure that the population has not changed during shipping or storage. This is a critical step is necessary to provide a high degree of assurance that the BIs are viable to support verification that finished product is successfully sterilized through the (b)(4) Sterilization process. Additionally, the inspection revealed that critical information such as the batch number and expiration date of the BI used in the sterile load is not documented on the post-sterilization B1 Test Reports, which are used as part of the finished device acceptance and release process.\n\n2) Your firm's incoming inspection and acceptance procedure for Sterile Potties (M1421, M1422) used for storing ultrasound cleaned NeoZoline Ventilation Tubes is not adequately established. The inspection revealed that your firm accepts incoming sterile pottle lots without a Certificate of Sterilization from the supplier. (b)(4). Your firm stated that no additional testing or verification is performed to ensure the sterility of the incoming potties. (b)(4)\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on June 1, 2024. Your firm concluded that a risk analysis of the specific observation indicates no risk to end users for products currently in distribution and manufacturing. That conclusion is based on the following factors:\n\nThe (b)(4) Biological Indicator is an off the shelf product from supplier where (b)(4) has claimed compliance with ISO 11138-1:2017 and ISO 11138-2:2017.\n\nThe BI is packaged in a foil pouch designed to protect the product from humidity excursions.\n\nThe potties are used to store non-sterile Ventilation Tubes hence the sterility of the pottle is not a requirement.\n\nAdditionally, your firm has outlined a plan with the following actions to be completed by December 1, 2024, which includes the following actions:\n\n(b)(4)\n\nBased on your firm's response there is an ambiguity in the definition of the term `pottle' and whether it is required to be sterile or not. (b)(4) your firm's response states that there is no risk for the stenle products manufactured at your facility because the BIs that they use conform to ISO 11138-1:2017 and ISO 11138-2:2017, and that they are in their sterile packaging until they are needed. However, the inspection demonstrated that your firm does not do any testing to verify that the BIs purchased for the purpose of demonstrating that terminal sterilization is achieved, are actually viable when they are used. Additionally, the inspection revealed that they do not capture key data such as BI batch number and expiration date, and thus if a BI falsely indicated that a sterilization was successful, there is no mechanism by which your firm can trace the lots of sterile products back to a failed BI.\n\nAdditionally, your firm did not include documentation or evidence of the corrections or corrective actions because they are in progress and have not been completed. Additionally, given the observations described above, your firm has not provided a commitment to conduct a retrospective assessment of all finished devices whose sterilization was verified using Biological Indicator (b)(4) to determine whether sterility was compromised.\n\n2. Failure to ensure that where the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a). For example:\n\n1) Your firm's ultrasonic cleaning process using the (b)(4) Cleaner (b)(4) is not adequately validated according to your firm's Manufacturing Process (b)(4). During the inspection, FDA's investigator revealed that the ultrasonic cleaning process was not adequately validated because critical details—such as the description of the NeoZoline Ventilation Tube (including part number, size, and shape), the number of validation batches (runs), validation batch size, and sample size used—were not documented.\n\n2) During the inspection, your firm stated that it had not validated the (b)(4) process for the NeoZoline Ventilation Tube (b)(4). Your firm stated that the (b)(4). Adept Medical also confirmed during the inspection that (b)(4) had not validated the NeoZoline Ventilation Tube (b)(4) and that prior to Spring 2023, (b)(4) the NeoZoline Ventilation Tube (b)(4) who also did not have a (b)(4) NeoZoline Ventilation Tube.\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates its Initial Action was completed on June 1, 2024. Your firm concluded that there is no risk to end users for products currently in supply and with distributors, based on the following factors:\n\nThere is an existing validated sterilization process indicating a sterility assurance level of (b)(4)\n\nAnnual bioburden results of pre-cleaned devices have bioburden levels below (b)(4) CFU.\n\nCurrent validation data, although not well documented in its sample selection and setting, still indicated the current setting provided adequate bioburden results, well within the capability of the sterilization process.\n\nAdditionally, your firm has outlined a plan to be completed by June 1, 2025, which includes the following actions:\n\n(b)(4)\n\nHowever, your firm has not provided any evidence to substantiate your claims that the (b)(4) sterility assurance level or the bioburden limits below (b)(4) CFU were consistently achievable. The inspection raised concerns about your firm sterilization process, as discussed in the above section regarding compliance with 21 CFR 820.80(a). It is noteworthy that FDA requested validation documents for the (b)(4) Cleaner during the May 2024 inspection and did not receive any documentation to indicate that this process was validated.\n\n3. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100. For example:\n\nYour firm's Corrective and Preventive Action (CAPA) procedure (M05-03) fails to ensure that:\n\n1) The quality data is adequately analyzed to identify potential and existing causes of nonconformances or other quality issues. Your firm stated to the FDA investigator that, although data is analyzed, they do not evaluate the results to determine whether any corrective or preventive actions are necessary, as required by 21 CFR 820.100(a)(3).\n\n2) Your firm failed to adequately verify the effectiveness of corrective actions for several CAPAs before closing them. Specifically, CAPAs CA-459, CA-438, and CA-437 were closed after implementing corrective actions, but your firm did not verify the effectiveness of these actions, as required by 21 CFR 820.100(a)(4).\n\n3) CA-429 was closed on February 16, 2023; at the time of the inspection, your firm stated that they had not started any of the corrective actions identified in the CAPA. As a result of the discussion during the inspection, your firm volunteered to mark the CAPA as 'open,' so that the corrective actions could be implemented.\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that although procedure (b)(4) the procedure did not instruct how to this data should be analyzed, and what subsequent actions should be taken once the data analysis is complete. However, your firm's procedure (b)(4)\n\nYour firm has outlined the following plan to be completed by April 1, 2025, which includes the following actions:\n\n(b)(4)\n\nHowever, your firm's response does not identify conducting a retrospective analysis for all past CAPAs, to determine the impact of the lack of data analysis, and whether the appropriate corrective and\u002For preventive action was taken to address each CAPA's root cause. Additionally, your firm did not identify what actions it would take to address the lack of implementation of identified corrective actions and whether that issue is a systemic problem.\n\n4. Failure to establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product; and failure to ensure that the evaluation includes a determination of the need for an investigation, as required by 21 CFR 820.90(a). For example:\n\nThe FDA investigator reviewed six NC records related to your firm's NeoZoline Ventilation Tubes. All six NC records were closed (NC-2516, NC-2767, NC-2641, NC-2640, NC-2738, NC-2523), but showed the following deficiencies in documentation:\n\nThe NC records did not adequately document the evaluation of the identified nonconformities.\n\nThe rationale for not conducting related investigations was inadequately documented in all six NC records.\n\nYour firm explained that incoming NeoZoline Ventilation Tubes (b)(4) are not inspected upon arrival. (b)(4). Your firm further stated that they (b)(4). This target achievement was cited as the reason for not taking further action.\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that there is no risk to end users for products currently in supply and with distributors. That conclusion is based on postmarket surveillance data, which shows no product safety or performance complaints since the product's launch. However, a lack of documented safety signals does not ensure that nonconforming product was controlled and not introduced into commerce.\n\nAdditionally, your firm has outlined a plan to be completed by April 1, 2025, which includes the following actions:\n\n(b)(4)\n\nHowever, your firm did not include documentation to demonstrate that it has evaluated or will evaluate all past non-conformances against your new procedure to determine whether additional corrective action was required to address the non-conformances identified in your NC Records.\n\n5. Failure to define the type and extent of control to be exercised over the product, services, suppliers, contractors, and consultants, based on the evaluation results, as required by 21 CFR 820.50(a)(2). For example:\n\nDuring the inspection, your firm was asked whether the (b)(4) for the NeoZoline ventilation tubes was validated (b)(4). Your firm stated you have no knowledge or documentation regarding whether the (b)(4) for the NeoZoline Ventilation Tubes had been properly validated. (b)(4) Adept Medical learned the (b)(4) Adept Medical received (b)(4) units of NeoZoline Ventilation Tubes in various types from (b)(4) between June 2023 and November 2023. They released (b)(4) units ((b)(4) boxes) of the NeoZoline Ventilation Tubes to the United States. Prior to June 2023, all NeoZoline Ventilation Tubes were (b)(4). Adept has failed to ensure that the conditions of the supplier agreement were adhered to by your supplier.\n\nWe reviewed your firm's response dated June 13, 2024, and conclude that it is not adequate. Your firm's response indicates that its Initial Action was completed on May 29, 2024. Your firm concluded that there is no risk to the end users for products currently in supply and with distributors, based on the following considerations:\n\nThe post-market periodic safety update report (PSUR) on Ventilation Tubes supplied by (b)(4) indicated no adverse events.\n\n(b)(4)\n\nPost market surveillance data indicated we have had no product safety or performance complaints since product launch.\n\nHowever, a lack of adverse events in post market safety signals does not provide assurance that the device meets its design specifications, in light of the fact that, Adept Medical was unaware that your supplier (b)(4) the NeoZoline Ventilation Tube (b)(4) did not have any documentation that the (b)(4) device was validated.\n\nAdditionally, your firm has outlined a plan to be completed by June 1, 2025, which includes the following actions:\n\n(b)(4)\n\nHowever, based on your firm's response, it is unclear how you intend to evaluate suppliers' compliance with 21 CFR Part 820, the Quality System Regulation.\n\nOur inspection also revealed that the NeoZoline Ventilation Tubes are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PM_A) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, in that your firm did not notify FDA regarding a significant change or modification in the device that could significantly affect the safety or effectiveness of the device, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 C.F.R. 807.81 (a)(3)(i).\n\nSpecifically, your firm has modified the NeoZoline Ventilation Tubes cleared under K061058. The modification involves the use of a (b)(4) which was not cleared in the original submission and is a change that could significantly affect the safety or effectiveness of the device. This modification necessitates a comprehensive risk assessment to ensure the device remains safe and effective. A new biocompatibility evaluation is required to determine if (b)(4). Any (b)(4) may affect how the device can be safely and effectively sterilized. Thus, your sterilization processes must be validated for the (b)(4) to ensure that it can be properly sterilized without (b)(4) becoming unsafe. The change in (b)(4) may alter the device's performance or specifications, so a thorough re-evaluation is necessary to ensure it still meets all necessary standards and functions as intended. Due to the (b)(4) modification and its potential impact on the device's safety and performance, a new 510(k) submission is required before marketing the modified device in the United States.\n\nFor a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)] The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fd efault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm's response(s) and the need to re-inspect your firm's facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm's response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #692226 when replying. If you have any questions about the contents of this letter, please contact: Shu-Chen Peng, Ph.D. at 301-796-6481.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nMalvina B. Eydelman, M.D.\n\nDirector\n\nOHT1: Office of Ophthalmic, Anesthesia,\n\nRespiratory, ENT and Dental Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\n(b)(4), Registrar Corp.,\n\n144 Research Drive,\n\nHampton, Virginia,\n\nUSA 23666\n\nPhone: Tel: 1-757-224-0177, Ext. (b)(4)\n\nEmail:(b)(4)@registrarcorp.com","Adept Medical Ltd.","adept-medical-ltd-692226-10112024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadept-medical-ltd-692226-10112024","2026-10-26T08:07:50.120298+00:00","2024-11-26","692226","Mr. Murray Fenton","2026-08-19T17:57:49.713+00:00","Via Email","2024-10-11",{"id":75,"raw":76,"subject":38,"body_html":81,"body_text":82,"firm_name":83,"letter_id":84,"created_at":85,"fei_number":19,"letter_url":86,"updated_at":87,"action_type":22,"case_status":88,"posted_date":89,"marcs_cms_no":90,"product_type":48,"closeout_date":91,"issuing_office":37,"recipient_name":92,"body_fetched_at":93,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":94,"medical_device_id":19,"response_letter_date":19},1671,[77,78,79,37,38,13,80,13],"\u003Ctime datetime=\"2023-12-26T14:20:00Z\">12\u002F26\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-09-22T04:00:00Z\">09\u002F22\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsonesta-medical-ab-667325-09222023\">Sonesta Medical AB\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsonesta-medical-ab-667325-12042023\">\u003Ctime datetime=\"2024-02-28T05:00:00Z\">02\u002F28\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Pelin Sari\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sonesta Medical AB\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Industrivagen 7\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>171 48\u003C\u002Fspan> \u003Cspan>Solna\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sweden\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)@sonestamedical.se\"> (b)(6)@sonestamedical.se\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 22, 2023\u003Cbr>\n\u003Cbr>\nDear Ms. Sari:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Solna, Sweden on June 5, 2023, through June 7, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Model 6210 radiographic table and Model S2 and S3 cystometric tables. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from you dated June 1, 2023, August 11, 2023, and September 1, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specific requirements, as required by 21 CFR 820.50(a). Specifically, your firm’s current purchasing controls procedure, Supplier Evaluation, Rev 2, dated April 7, 2021, fails to define the frequency, type, and extent of control to exercise over suppliers, contractors, and consultants, based on the results of periodic evaluation. Additionally, your firm has not evaluated your contract repair\u002Fservicer, and the current contract Quality Assurance &amp; Regulatory Affairs consultant. Further, your firm failed to maintain records covering evaluation of the current contract Quality Assurance &amp; Regulatory Affairs consultant, who has been assisting your firm in overseeing and maintaining their Quality System procedures since the year 2020.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses dated June 1, 2023, August 11, 2023, and September 1, 2023, and conclude that they are not adequate. Your firm’s responses state that you have revised the Supplier Evaluation SOP 1) to include the frequency and\u002For period for evaluation of suppliers, contractors, and consultants, 2) to include the type and extent of control to exercise over suppliers, contractors and consultants based on the results of the periodic evaluation, 3) to include evaluation of the contract repair\u002Fservicer for the Model 6210 radiographic table and Model S2 and S3 cystometric tables, and 4) to include requirements for assessment of contractors, consultants, and evaluation of the current contract QA\u002FRA consultant. You state that appropriate staff has received training on the revised SOPs and forms. You have not completed the assessment and evaluation of the contract repair\u002Fservicer and your current contract Quality Assurance &amp; Regulatory Affairs consultant. Additionally, you have not conducted a retrospective review of related documentation to ensure compliance with updated procedures. Although your firm’s responses state that you have updated the Supplier Evaluation procedures, the revised procedures were not included for our evaluation.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically, your firm’s procedure, Process description deviation management, Rev 1, dated November 25, 2020, fails to define requirements for review of complaints to determine if they should be evaluated for Medical Device Reporting. Additionally, your firm’s complaint records do not consistently include the dates and results of investigation (e.g., covering failures involving welding breakages and safety switches). Further, a review of a sampling of complaint records found five of five records do not list the Unique Device Identification (UDI) code for the subject devices.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses dated June 1, 2023, August 11, 2023, and September 1, 2023, and conclude that they are not adequate. Your firm’s responses state that you have revised the complaint handling SOP to require dates and results of investigations and UDI code for subject devices. You also state that you have revised several forms including CAPA form and Non-Conformance Report form and trained the staff on the revised SOPs and forms. Also, you have not completed a review of complaints per the revised procedure to evaluate reportability for Medical Device Reporting and have not conducted a retrospective review of related documentation to ensure compliance with updated procedures. Although your responses state that you have updated the complaint handling procedures, the revised procedures were not included for our evaluation.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain procedures to ensure that the design requirements relating to a device are appropriate and address the intended use of the device, including the needs of the user and patient, as required by 21 CFR 820.30(c). Specifically, your firm does not have procedures for defining a mechanism to resolve incomplete, ambiguous, or conflicting design requirements.\u003C\u002Fp>\n\n\u003Cp>As of September 13, 2023, you have not provided a response to this observation.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain procedures for validating the device design under defined operating conditions on initial production units, lots, or batches, or their equivalents, as required by 21 CFR 820.30(g). Specifically, your firm’s design validation procedure, Rev 1, dated January 22, 2021, does not fully define requirements to ensure devices are designed to meet user needs and intended uses. For example, the procedure fails to a) require the evaluation to be carried out on initial production units or their equivalents; b) require the evaluation to be carried out under actual or simulated use conditions.\u003C\u002Fp>\n\n\u003Cp>As of September 13, 2023, you have not provided a response to this observation.\u003C\u002Fp>\n\n\u003Cp>5. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). Specifically, your firm does not have procedures for defining control for changes to existing device design requirements and design results, to include a) describing the changes and the reason for the changes; b) determining the need to verify and\u002For validate the changes; c) determining impact on the design risk analysis; d) determine any new regulatory requirements, such as premarket clearance or approval, as needed.\u003C\u002Fp>\n\n\u003Cp>As of September 13, 2023, you have not provided a response to this observation.\u003C\u002Fp>\n\n\u003Cp>6. Failure to establish and maintain procedures to control all documents, as required by 21 CFR 820.40. Specifically, your firm’s document controls procedure, Rev 1, dated December 15, 2020, does not require the approval of quality system documents to include the signature of the approving personnel and the date of that signature. Additionally, your firm has not fully implemented the current document controls procedure, which requires that you assign a unique document number to each quality system document, as multiple procedures do not feature a unique document number.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s responses dated June 1, 2023, August 11, 2023, and September 1, 2023, and conclude that they are not adequate. Your firm’s responses state that you have revised the document controls SOP to implement Acrobat sign and included the requirement of signature of approving personnel and date on the approval of quality system documents, as well as to include a unique document number to each quality system document. However, you have not conducted a retrospective review of related documentation to ensure compliance with updated procedures. Although your response states that you have updated the document controls procedures, the revised procedures were not included for our evaluation.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case #667325 when replying. If you have any questions about the contents of this letter, please contact: Lu Jiang at +1(240)402-5779.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Robert Ochs, Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT8: Office of Radiological Health\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>Cc:\u003Cbr>\nGreg Swanson\u003Cbr>\nUS Agent\u003Cbr>\nEmergo Global Representation LLC\u003Cbr>\n2500 Bee Cave Road, Building 1, Suite 300\u003Cbr>\nAustin, Texas 78746\u003Cbr>\nUSAgent@UL.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nPelin Sari\n\nRecipient Title\n\nChief Executive Officer\n\nSonesta Medical AB\n\nIndustrivagen 7\n\n171 48 Solna\n\nSweden\n\n(b)(6)@sonestamedical.se\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nSeptember 22, 2023\n\nDear Ms. Sari:\n\nDuring an inspection of your firm located in Solna, Sweden on June 5, 2023, through June 7, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Model 6210 radiographic table and Model S2 and S3 cystometric tables. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses from you dated June 1, 2023, August 11, 2023, and September 1, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address these responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specific requirements, as required by 21 CFR 820.50(a). Specifically, your firm’s current purchasing controls procedure, Supplier Evaluation, Rev 2, dated April 7, 2021, fails to define the frequency, type, and extent of control to exercise over suppliers, contractors, and consultants, based on the results of periodic evaluation. Additionally, your firm has not evaluated your contract repair\u002Fservicer, and the current contract Quality Assurance & Regulatory Affairs consultant. Further, your firm failed to maintain records covering evaluation of the current contract Quality Assurance & Regulatory Affairs consultant, who has been assisting your firm in overseeing and maintaining their Quality System procedures since the year 2020.\n\nWe reviewed your firm’s responses dated June 1, 2023, August 11, 2023, and September 1, 2023, and conclude that they are not adequate. Your firm’s responses state that you have revised the Supplier Evaluation SOP 1) to include the frequency and\u002For period for evaluation of suppliers, contractors, and consultants, 2) to include the type and extent of control to exercise over suppliers, contractors and consultants based on the results of the periodic evaluation, 3) to include evaluation of the contract repair\u002Fservicer for the Model 6210 radiographic table and Model S2 and S3 cystometric tables, and 4) to include requirements for assessment of contractors, consultants, and evaluation of the current contract QA\u002FRA consultant. You state that appropriate staff has received training on the revised SOPs and forms. You have not completed the assessment and evaluation of the contract repair\u002Fservicer and your current contract Quality Assurance & Regulatory Affairs consultant. Additionally, you have not conducted a retrospective review of related documentation to ensure compliance with updated procedures. Although your firm’s responses state that you have updated the Supplier Evaluation procedures, the revised procedures were not included for our evaluation.\n\n2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically, your firm’s procedure, Process description deviation management, Rev 1, dated November 25, 2020, fails to define requirements for review of complaints to determine if they should be evaluated for Medical Device Reporting. Additionally, your firm’s complaint records do not consistently include the dates and results of investigation (e.g., covering failures involving welding breakages and safety switches). Further, a review of a sampling of complaint records found five of five records do not list the Unique Device Identification (UDI) code for the subject devices.\n\nWe reviewed your firm’s responses dated June 1, 2023, August 11, 2023, and September 1, 2023, and conclude that they are not adequate. Your firm’s responses state that you have revised the complaint handling SOP to require dates and results of investigations and UDI code for subject devices. You also state that you have revised several forms including CAPA form and Non-Conformance Report form and trained the staff on the revised SOPs and forms. Also, you have not completed a review of complaints per the revised procedure to evaluate reportability for Medical Device Reporting and have not conducted a retrospective review of related documentation to ensure compliance with updated procedures. Although your responses state that you have updated the complaint handling procedures, the revised procedures were not included for our evaluation.\n\n3. Failure to establish and maintain procedures to ensure that the design requirements relating to a device are appropriate and address the intended use of the device, including the needs of the user and patient, as required by 21 CFR 820.30(c). Specifically, your firm does not have procedures for defining a mechanism to resolve incomplete, ambiguous, or conflicting design requirements.\n\nAs of September 13, 2023, you have not provided a response to this observation.\n\n4. Failure to establish and maintain procedures for validating the device design under defined operating conditions on initial production units, lots, or batches, or their equivalents, as required by 21 CFR 820.30(g). Specifically, your firm’s design validation procedure, Rev 1, dated January 22, 2021, does not fully define requirements to ensure devices are designed to meet user needs and intended uses. For example, the procedure fails to a) require the evaluation to be carried out on initial production units or their equivalents; b) require the evaluation to be carried out under actual or simulated use conditions.\n\nAs of September 13, 2023, you have not provided a response to this observation.\n\n5. Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). Specifically, your firm does not have procedures for defining control for changes to existing device design requirements and design results, to include a) describing the changes and the reason for the changes; b) determining the need to verify and\u002For validate the changes; c) determining impact on the design risk analysis; d) determine any new regulatory requirements, such as premarket clearance or approval, as needed.\n\nAs of September 13, 2023, you have not provided a response to this observation.\n\n6. Failure to establish and maintain procedures to control all documents, as required by 21 CFR 820.40. Specifically, your firm’s document controls procedure, Rev 1, dated December 15, 2020, does not require the approval of quality system documents to include the signature of the approving personnel and the date of that signature. Additionally, your firm has not fully implemented the current document controls procedure, which requires that you assign a unique document number to each quality system document, as multiple procedures do not feature a unique document number.\n\nWe reviewed your firm’s responses dated June 1, 2023, August 11, 2023, and September 1, 2023, and conclude that they are not adequate. Your firm’s responses state that you have revised the document controls SOP to implement Acrobat sign and included the requirement of signature of approving personnel and date on the approval of quality system documents, as well as to include a unique document number to each quality system document. However, you have not conducted a retrospective review of related documentation to ensure compliance with updated procedures. Although your response states that you have updated the document controls procedures, the revised procedures were not included for our evaluation.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case #667325 when replying. If you have any questions about the contents of this letter, please contact: Lu Jiang at +1(240)402-5779.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nRobert Ochs, Ph.D.\n\nDirector\n\nOHT8: Office of Radiological Health\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc:\n\nGreg Swanson\n\nUS Agent\n\nEmergo Global Representation LLC\n\n2500 Bee Cave Road, Building 1, Suite 300\n\nAustin, Texas 78746\n\nUSAgent@UL.com","Sonesta Medical AB","sonesta-medical-ab-667325-09222023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsonesta-medical-ab-667325-09222023","2026-10-26T08:10:01.487143+00:00","Closed Out","2023-12-26","667325","2024-02-28","Pelin Sari","2026-08-20T00:25:09.984+00:00","2023-09-22",{"id":96,"raw":97,"subject":102,"body_html":103,"body_text":104,"firm_name":105,"letter_id":106,"created_at":65,"fei_number":19,"letter_url":107,"updated_at":108,"action_type":22,"case_status":23,"posted_date":109,"marcs_cms_no":110,"product_type":26,"closeout_date":19,"issuing_office":101,"recipient_name":111,"body_fetched_at":112,"delivery_method":51,"recipient_title":19,"reference_number":19,"action_taken_date":113,"medical_device_id":19,"response_letter_date":19},1227,[98,99,100,101,102,13,13,13],"\u003Ctime datetime=\"2024-10-01T13:20:00Z\">10\u002F01\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-06T04:00:00Z\">09\u002F06\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fclean-solutions-llc-686995-09062024\">Clean Solutions LLC\u003C\u002Fa>","Division of Pharmaceutical Quality Operations I","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Asim Ozcan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Clean Solutions LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>791 Paulison Ave., Suite 5\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Clifton\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07011-3608\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:asim@cleansolutionsnj.com\"> asim@cleansolutionsnj.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong>\u003Cbr>\nCMS #686995\u003C\u002Fp>\n\n\u003Cp>9\u002F6\u002F2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Ozcan:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Clean Solutions LLC, FEI 3012305678, at 791 Paulison Ave., Suite 5, Clifton, NJ, from May 6 to 10, 2024.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your May 29, 2024 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures over-the-counter (OTC) topical drug products, such as antibacterial hand soaps containing benzalkonium chloride. You failed to perform adequate identity testing of each component lot used in the manufacture of your drug products. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications before use in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and conduct for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to perform appropriate testing on your hand sanitizer and antibacterial hand soap drug products prior to release for distribution. Specifically, during the inspection, you stated that no chemical or microbiological analyses are performed on your finished drug products.\u003C\u002Fp>\n\n\u003Cp>Testing is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Because you lacked adequate testing of each batch of your drug products, you do not know whether they conform to all appropriate finished product specifications and are suitable for release to consumers.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to validate the processes used to manufacture your drug products. You also failed to qualify the equipment used to manufacture your drug products.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>Without adequate process validation, incorporating all manufacturing inputs and parameters that can affect product quality, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications. See FDA's guidance for industry, \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\n\n\u003Cp>• Establishment of adequate procedures describing complaint handling, change control, and employee training procedures (21 CFR 211.22(d)).\u003Cbr>\n• Establishment of an adequate ongoing stability program (21 CFR 211.166(a)).\u003Cbr>\n• Performance of periodic (i.e., at least annual) product reviews (21 CFR 211.180(e)).\u003Cbr>\n• Adequate equipment cleaning and cleaning procedures, as well as appropriate cleaning validation (21 CFR 211.67(a) and 67(b)).\u003Cbr>\n• Appropriate batch production and control records that include documentation of the accomplishment of each significant step in manufacturing of your drug products (21 CFR 211.188(b)).\u003C\u002Fp>\n\n\u003Cp>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document Quality Systems approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In response to this letter, clarify whether you intend to continue manufacturing drugs at this or any other facility.\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if you continue manufacturing drugs. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003Cbr>\n\u003Cbr>\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic response to orapharm1_responses@fda.hhs.gov. Your written notification should refer to Warning Letter CMS # 686995 and include FEI: 3012305678.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, contact Compliance Officer Barbara Wilimczyk-Macri at barbara.wilimczyk@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lisa Harlan\u003Cbr>\nProgram Division Director\u003Cbr>\nOPQO Division I\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Asim Ozcan\n\nRecipient Title\n\nPresident\n\nClean Solutions LLC\n\n791 Paulison Ave., Suite 5\n\nClifton, NJ 07011-3608\n\nUnited States\n\nasim@cleansolutionsnj.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWarning Letter\n\nCMS #686995\n\n9\u002F6\u002F2024\n\nDear Mr. Ozcan:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Clean Solutions LLC, FEI 3012305678, at 791 Paulison Ave., Suite 5, Clifton, NJ, from May 6 to 10, 2024.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your May 29, 2024 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYour firm manufactures over-the-counter (OTC) topical drug products, such as antibacterial hand soaps containing benzalkonium chloride. You failed to perform adequate identity testing of each component lot used in the manufacture of your drug products. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\n\nWithout adequate testing, you do not have scientific evidence that the components conform to appropriate specifications before use in the manufacture of your drug products.\n\n2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and conduct for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\n\nYour firm failed to perform appropriate testing on your hand sanitizer and antibacterial hand soap drug products prior to release for distribution. Specifically, during the inspection, you stated that no chemical or microbiological analyses are performed on your finished drug products.\n\nTesting is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Because you lacked adequate testing of each batch of your drug products, you do not know whether they conform to all appropriate finished product specifications and are suitable for release to consumers.\n\n3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYou failed to validate the processes used to manufacture your drug products. You also failed to qualify the equipment used to manufacture your drug products.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\n\nWithout adequate process validation, incorporating all manufacturing inputs and parameters that can affect product quality, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications. See FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\n\n• Establishment of adequate procedures describing complaint handling, change control, and employee training procedures (21 CFR 211.22(d)).\n\n• Establishment of an adequate ongoing stability program (21 CFR 211.166(a)).\n\n• Performance of periodic (i.e., at least annual) product reviews (21 CFR 211.180(e)).\n\n• Adequate equipment cleaning and cleaning procedures, as well as appropriate cleaning validation (21 CFR 211.67(a) and 67(b)).\n\n• Appropriate batch production and control records that include documentation of the accomplishment of each significant step in manufacturing of your drug products (21 CFR 211.188(b)).\n\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document Quality Systems approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nCGMP Consultant Recommended\n\nIn response to this letter, clarify whether you intend to continue manufacturing drugs at this or any other facility.\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if you continue manufacturing drugs. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic response to orapharm1_responses@fda.hhs.gov. Your written notification should refer to Warning Letter CMS # 686995 and include FEI: 3012305678.\n\nIf you have any questions, contact Compliance Officer Barbara Wilimczyk-Macri at barbara.wilimczyk@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nLisa Harlan\n\nProgram Division Director\n\nOPQO Division I\n\nU.S. Food and Drug Administration","Clean Solutions LLC","clean-solutions-llc-686995-09062024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fclean-solutions-llc-686995-09062024","2026-10-26T08:08:15.745138+00:00","2024-10-01","686995","Mr. Asim Ozcan","2026-08-19T22:31:53.814+00:00","2024-09-06",{"id":115,"raw":116,"subject":121,"body_html":122,"body_text":123,"firm_name":124,"letter_id":125,"created_at":126,"fei_number":19,"letter_url":127,"updated_at":128,"action_type":22,"case_status":23,"posted_date":129,"marcs_cms_no":130,"product_type":26,"closeout_date":19,"issuing_office":120,"recipient_name":131,"body_fetched_at":132,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":133,"medical_device_id":19,"response_letter_date":19},2895,[117,118,119,120,121,13,13,13],"\u003Ctime datetime=\"2022-02-01T14:20:00Z\">02\u002F01\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-10-22T04:00:00Z\">10\u002F22\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fapplied-health-solutions-inc-616778-10222021\">Applied Health Solutions, Inc.\u003C\u002Fa>","Office of Human and Animal Food Operations - Division IV West","New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>William Evans\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Applied Health Solutions, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11231 N 84th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations - Division IV West\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 22, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\n\u003Cstrong>Ref: CMS Case # 616778\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Evans:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fstore.appliedhealth.com in July-August 2021 and has determined that you take orders there for the Applied Health Solutions brand products B Complex, Daily Detox, CellRenewPRO, CellRenewSTS, and PowerZyme Prime, and the NutriBiotic brand products Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate. We also reviewed your website at the Internet address https:\u002F\u002Fappliedhealth.com, which directs consumers to your website https:\u002F\u002Fstore.appliedhealth.com to purchase your products. The claims on your websites establish these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Examples of the website claims that establish the intended use of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>B Complex product:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the “Prevent MRSA Infection” blog post (https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F), which hyperlinks to the product webpage for B Complex:\u003C\u002Fp>\n\n\u003Cp>• “Prevent MRSA Infection . . . Annihilate infections before they start -Strengthen Your Immunity[.] Anything that can be done to boost your immune system will benefit you when you come in contact with this bacteria. . . . make sure you are getting plenty of immune boosting vitamins. . . . B-complex . . .”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Daily Detox product:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the Daily Detox product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fcollections\u002Fdetox-cleansing-support\u002Fproducts\u002Fdaily-detox-toxin-binding-agents):\u003C\u002Fp>\n\n\u003Cp>• “Broccoli Extract – BroccoSinolate [an ingredient in Daily Detox] . . . rich in . . . glucosinolates . . . Glucosinolates . . . help lower cancer risks and protect against cardiovascular disease. Another benefit . . . is the ability to help fight bacterial, viral, and fungal infections.”\u003C\u002Fp>\n\n\u003Cp>On the “Prevent MRSA Infection” blog post (https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F), which hyperlinks to the product webpage for Daily Detox:\u003C\u002Fp>\n\n\u003Cp>• “Regular use of Daily Detox offers powerful antioxidant protection against seasonal colds and flu.”\u003C\u002Fp>\n\n\u003Cp>• “NATURAL TREATMENT: Good riddance “SuperBug”! These nutrients contain anti-microbial and anti-bacterial properties: Applied Health’s Daily Detox . . .”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>PowerZyme Prime product:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the PowerZyme Prime ingredients webpage (https:\u002F\u002Fappliedhealth.com\u002Fpowerzyme-digestive-enzymes\u002Fpowerzyme-ingredients\u002F):\u003C\u002Fp>\n\n\u003Cp>• “Lysozyme [an ingredient in PowerZyme Prime] . . . Documented in human studies to inhibit the growth of Candida albicans.”\u003C\u002Fp>\n\n\u003Cp>• “Serratia peptidase [an ingredient in PowerZyme Prime] . . . exhibits well documented fibrinolytic (prevention of blood clots), anti-inflammatory, and anti-edematous (prevents swelling of tissues from water entrapment – edema) activities and lessens the viscosity of exudates (a fluid of protein and cellular elements that escapes blood vessels due to inflammation and settles in nearby tissues).”\u003C\u002Fp>\n\n\u003Cp>On the “Chronic Candida Syndrome” blog post (https:\u002F\u002Fappliedhealth.com\u002Fchronic-candida-syndrome\u002F):\u003C\u002Fp>\n\n\u003Cp>• “What causes Candidiasis? . . . Other contributing factors to Candida imbalance are . . . Lack of digestive enzymes . . .” [the phrase “digestive enzymes” hyperlinks to the PowerZyme Prime product webpage]\u003C\u002Fp>\n\n\u003Cp>On the “Chronic Candida Syndrome Part 2” blog post (https:\u002F\u002Fappliedhealth.com\u002Fchronic-candida-syndrome-part-2\u002F):\u003Cbr>\n\u003Cbr>\n• “Incidence of Candidiasis is rapidly increasing. Several reasons for this are: . . . Lack of proper digestive enzymes in our diet. . . . As always, we prefer to recommend more holistic methods for our readers. However, remember that it is important to rotate even natural therapies, because resistant strains of Candida mutate easily. . . . Nutrients and antioxidants that support the immune system are also important, such as: Digestive Enzymes . . .” [the PowerZyme Prime product is also referred to as “Digestive Enzymes” on the PowerZyme Prime product webpage]\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Grapefruit Seed Extract CapsulesPlus product:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the Grapefruit Seed Extract CapsulesPlus product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fproducts\u002Fnutribiotic-grapefruit-seed-extract-with-echinacea-and-artemisia-annua):\u003C\u002Fp>\n\n\u003Cp>• “It is effective against pathogens because it belongs to a family of compounds known as quaternary compounds.”\u003C\u002Fp>\n\n\u003Cp>• “Additional information to consider on Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract CapsulesPlus] is available at: Grapefruit Seed Extract for Cold\u002FFlu Season:\u003Cbr>\nhttps:\u002F\u002Fappliedhealth.com\u002Fgrapefruit-seed-extract-rx-for-cold-and-flu-season\u002F . . . Prevent MRSA Infection: https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F . . .”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Grapefruit Seed Extract Liquid Concentrate product:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the Grapefruit Seed Extract Liquid Concentrate product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fproducts\u002Fnutribiotic-grapefruit-seed-extract-liquid):\u003C\u002Fp>\n\n\u003Cp>• “Additional information to consider on Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract Liquid Concentrate]: Grapefruit Seed Extract for Cold\u002FFlu Season: https:\u002F\u002Fappliedhealth.com\u002Fgrapefruit-seed-extract-rx-for-cold-and-flu-season\u002F . . . Prevent MRSA Infection: https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F . . .”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Grapefruit Seed Extract Liquid Concentrate and Grapefruit Seed Extract CapsulesPlus products:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the “Prevent MRSA Infection” blog post (https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F):\u003C\u002Fp>\n\n\u003Cp>• “NATURAL TREATMENT: Good riddance “SuperBug”! These nutrients contain anti-microbial and anti-bacterial properties . . . Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate]”\u003C\u002Fp>\n\n\u003Cp>On the “Benefits of Grapefruit seed Extract” webpage (https:\u002F\u002Fappliedhealth.com\u002Fbenefits-of-grapefruit-seed-extract\u002F), which hyperlinks to the Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate product webpages:\u003C\u002Fp>\n\n\u003Cp>• “Grapefruit Seed Extract (GSE) [an ingredient in Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate] . . . Used as a . . . antimicrobial product, it is known to be highly effective for fighting infection . . . Even in studies comparing its effectiveness to chlorine bleach, isopropyl alcohol, and colloidal silver, GSE has been found to be superior as an antimicrobial.”\u003C\u002Fp>\n\n\u003Cp>• “. . . research showing the effectiveness of GSE against AIDS.”\u003C\u002Fp>\n\n\u003Cp>• “All over the world, GSE has been used for killing a wide variety of bacteria (such as: Salmonella, E. coli, Staph and Strep germs), viruses, herpes, parasites, and fungi, including Candida. It is effective against more than 800 bacterial and viral strains, 100 strains of fungus, as well as a large number of single-cell and multi-celled parasites.”\u003C\u002Fp>\n\n\u003Cp>• “. . . the antimicrobial properties of GSE . . .”\u003C\u002Fp>\n\n\u003Cp>• “. . . antifungal properties of GSE have made it an important part of successful anti-Candida programs – a fact that has linked the names Candida and Grapefruit Seed Extract.”\u003C\u002Fp>\n\n\u003Cp>• “‘In the treatment of intestinal protozoan infections . . . [ellipsis in original] drugs are generally so toxic that they cannot be administered for prolonged periods of time, whereas GSE can be administered for weeks or months; prolonged treatment being essential for the cure of chronic protozoan infections . . . [ellipsis in original]’”\u003C\u002Fp>\n\n\u003Cp>• “To aid in the anti-Candida treatment, . . . GSE should be taken between meals. . . .”\u003C\u002Fp>\n\n\u003Cp>• “. . . a variety of other ailments can be helped by GSE, such as: . . .\u003C\u002Fp>\n\n\u003Cp>&nbsp; − AIDS – An increasing number of HIV positive people are able to improve their immune system by using GSE to fight viruses, bacteria, fungi, Candida, or parasites. . . .\u003Cbr>\n&nbsp; − Colds, flus, viruses – Take 10-15 drops, or 1-2 capsules\u002Ftablets, 3 times a day, at the first signs of cold or flu. . . .\u003Cbr>\n&nbsp; − Chronic Fatigue Syndrome – To generally build up immune system, gradually increase GSE amount to the recommended dosage for colds, flus, and viruses. . . .\u003Cbr>\n&nbsp; − Diarrhea – Use 15 to 20 drops in juice every four hours; no more than 60 drops per day. For parasites, higher doses may be necessary. . . .\u003Cbr>\n&nbsp; − Parasites . . .\u003Cbr>\n&nbsp; − Traveler’s Diarrhea (Montezuma’s Revenge) – Use 1-2 drops of GSE in a glass of water each day as a preventative. . . .\u003Cbr>\n&nbsp; − Ulcers . . .”\u003C\u002Fp>\n\n\u003Cp>On the “Grapefruit Seed Extract Rx for Cold and Flu Season” webpage (https:\u002F\u002Fappliedhealth.com\u002Fgrapefruit-seed-extract-rx-for-cold-and-flu-season\u002F), which hyperlinks to the Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate product webpages:\u003C\u002Fp>\n\n\u003Cp>• “Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate] RX for Cold and Flu Season”\u003C\u002Fp>\n\n\u003Cp>• “A Must-Have For Every Home During Cold and Flu Season”\u003C\u002Fp>\n\n\u003Cp>• “Whether it’s a sore throat, earache, viral infection, intestinal problem, or anything else related to a virus, fungus, or bad bacteria, if you are the main caregiver in your home, Grapefruit Seed Extract is a must-have for your cupboard.”\u003C\u002Fp>\n\n\u003Cp>• “. . . it is ‘Grapefruit’ Seed Extract (abbreviated as GSE or GFSE) that works as a natural antibiotic with anti-viral, anti-bacterial, and anti-fungal properties.”\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Internal Uses”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “Fight Colds, Flus, Viruses”\u003Cbr>\n&nbsp; − “Reach for the GSE at the first symptoms of flu or cold.”\u003Cbr>\n&nbsp; − “Traveler’s Diarrhea – As a preventative when traveling in areas with questionable water, mix 1 or 2 drops GSE in each glass of water, or on your toothbrush to disinfect and help prevent Traveler’s diarrhea.”\u003Cbr>\n&nbsp; − “Diarrhea – If you do experience a case of diarrhea, take 15 to 25 drops GSE every 3 to 4 hours in water or juice – no more than 75 drops per day. Or, 2 capsules\u002Ftablets (no more than 6 per day) every 4 hours.”\u003Cbr>\n&nbsp; − “Parasites . . . Use the same amount of GSE as for diarrhea, with possibly increasing to a maximum of 5 doses per day.”\u003Cbr>\n&nbsp; − “There have been anecdotal reports of GSE helping some serious illnesses, such as Chronic Fatigue Syndrome, AIDS, and even Cancer.”\u003Cbr>\n\u003Cbr>\n• “There are many more uses for GSE. Once you have successfully used it for something simple, like fighting a cold, you may find yourself reaching for it, regularly, whenever you find a need for its anti-viral, anti-fungal, and anti-bacterial properties.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>CellRenewPRO product:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the CellRenewPRO product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fcollections\u002Fjoint-soft-tissue-support\u002Fproducts\u002Fcellrenew-pro-hydrolyzed-collagen-type-ii):\u003C\u002Fp>\n\n\u003Cp>• “CellRenew PRO provides multi-dimensional nutritional components vital for repairing connective soft tissue (joints, skin, cardiovascular, etc.).”\u003C\u002Fp>\n\n\u003Cp>On the CellRenewPRO supplement facts and monograph webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fpages\u002Fcellrenew-pro-defined):\u003C\u002Fp>\n\n\u003Cp>• “CellRenew Pro is Ultimate Joint Repair”\u003C\u002Fp>\n\n\u003Cp>• “CellRenew PRO provides multi-dimensional nutritional components vital for repairing connective soft tissue (joints, skin, cardiovascular, etc.).”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>CellRenewPRO and CellRenewSTS products:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the CellRenewPRO (https:\u002F\u002Fstore.appliedhealth.com\u002Fpages\u002Fcellrenew-pro-defined) and CellRenewSTS (https:\u002F\u002Fstore.appliedhealth.com\u002Fpages\u002Fcellrenew-sts-supplement-facts-and-monograph) supplement facts and monograph webpages:\u003C\u002Fp>\n\n\u003Cp>• “CellRenew contains Hydrolyzed Collagen Type II derived from 100% pure chicken sternal cartilage. As an abundant source of naturally-occurring Hyaluronic Acid and Chondroitin Sulfates, Collagen Type II is easily absorbed to restore joint and cartilage health.”\u003C\u002Fp>\n\n\u003Cp>• “It is an absorbable hydrolyzed collagen type II product . . . that . . . relieves joint discomfort and increases mobility.”\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Research”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “Collagen Type II (CCII) [an ingredient in CellRenewPRO and CellRenewSTS] . . . can suppress pro-inflammatory activity to reduce joint discomfort and restore cartilage health. CCII from chicken sternal cartilage was shown to reduce chronic joint inflammation . . .”\u003Cbr>\n&nbsp; − “A three-month study recruited 60 patients with chronic joint inflammation to take CCII or a placebo. Results indicated CCII alleviated swollen and tender joints in the treatment group. Four patients in the treatment group had a complete remission of chronic joint inflammation.”\u003Cbr>\n&nbsp; − “Similarly, a pilot-study recruited female subjects with joint pain to take Hydrolyzed Collagen Type II for 42 days. Subjects reported a significant improvement in joint mobility and decrease in joint pain and stiffness.”\u003Cbr>\n&nbsp; − “CCII is evidenced to be effective among adolescents with chronic joint inflammation. A pilot-study administered CCII to 10 adolescent patients with chronic joint inflammation for 12 weeks. Eight patients experienced a reduction in swollen and tender joints. A similar pilot-study recruited nine adolescents with chronic joint inflammation to take an oral Collagen Type II, finding the supplement . . . reduced joint inflammation.”\u003Cbr>\n&nbsp; − “Chondroitin Sulfate (Component of Collagen Type II) [an ingredient in CellRenewPRO and CellRenewSTS] Naturally found in sternal chicken Collagen Type II, chondroitin sulfate has anti-inflammatory activity that reduces joint swelling, maintains synovial fluid levels, and spacing between the joints. Further, chondroitin sulfate reduces the proliferation of proteins to reduce joint inflammation.”\u003Cbr>\n&nbsp; − “A one-year study recruited 42 patients with knee pain to take chondroitin sulfate or a placebo. Subjects taking chondroitin sulfate had greater joint mobility and less pain, when compared to the placebo group.”\u003Cbr>\n&nbsp; − “A three-month study recruited 110 patients with knee pain to take chondroitin sulfate or a placebo finding supplementation improved knee function, reduced pain, and maintained joint space in the knee.”\u003Cbr>\n&nbsp; − “Researchers suggested chondroitin sulfate and glucosamine could repair and regenerate cartilage . . .”\u003Cbr>\n&nbsp; − “Hyaluronic Acid (Component of Collagen Type II) [an ingredient in CellRenewPRO and CellRenewSTS] . . . Studies have suggested hyaluronic acid has anti-inflammatory activity that suppresses pro-inflammatory and pain mechanisms in the body.”\u003Cbr>\n&nbsp; − “Researchers found that HA inhibited inflammatory cytokine activity in mice with inflamed joints. A similar study reviewed the effect of HA on acute and chronic inflammation in rats, finding HA suppressed inflammatory reactions . . .”\u003C\u002Fp>\n\n\u003Cp>On the homepage for the https:\u002F\u002Fappliedhealth.com website:\u003C\u002Fp>\n\n\u003Cp>• “How do you help knee pain? . . . CellRenew PRO is Extreme Knee Protection”\u003C\u002Fp>\n\n\u003Cp>• “CellRenew Additional Links . . . CellRenew Collagen Type II and Knee Pain . . . Is Collagen Type II A Cure For Arthritis And Heart Disease . . .”\u003Cbr>\n\u003Cbr>\n• In the response to the question “What is CellRenew?”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “Unlike other protocols for arthritis symptoms, whether prescription or natural, CellRenew is guaranteed for results.”\u003Cbr>\n&nbsp; − “It contains naturally occurring Hyaluronic Acid and Chondroitin Sulfate. The results of a human clinical trial using this material showed significant improvements in the reduction of joint swelling, tenderness, and pain, as well as successful increases in mobility.”\u003C\u002Fp>\n\n\u003Cp>• In the response to the question “Who is a good candidate to take CellRenew?”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “Although studies have shown that many different conditions respond to Collagen Type II, the conditions that have shown the greatest response are rheumatoid arthritis and osteoarthritis. If you have grown weary of traditional protocols that only cover-up symptoms and neglect to address the root cause, then you are an excellent candidate to begin a program of Collagen Type II.”\u003Cbr>\n&nbsp; − “CellRenew is also used as a preventative measure for athletes who . . . are looking for a way to maintain healthy joints prior to the onset of osteoarthritis.”\u003C\u002Fp>\n\n\u003Cp>• In response to the question “What will it do for me?”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “Collagen Type II (CTII) [an ingredient in CellRenewPRO and CellRenewSTS] has been suggested to offer significant benefits for some types of arthritis. . . . Rheumatoid arthritis (RA) is the most well known of the autoimmune types of arthritis. In the case of RA, the collagen in the joints is attacked.”\u003Cbr>\n&nbsp; − “Depending on the particular type of arthritis you experience, CTII goes to work in different ways. If you suffer from RA, CTII acts as an oral tolerization agent, instructing the body to stop the immune response to the collagen in the joints. . . . For those suffering from osteoarthritis, CTII provides the critical building blocks that restore a healthy state to the cartilage in the joints.”\u003Cbr>\n&nbsp; − “CellRenew is made from chicken sternal cartilage that contains the highest level of naturally occurring anti-inflammatory proteoglycans (Hyaluronic Acid and Chondroitin Sulfate A) of any other material tested, including shark cartilage. It is important to note that the combination of the proteoglycans and the Collagen Type II proteins . . . provide the building blocks required to rebuild lost cartilage to restore the joint to a normal state.”\u003C\u002Fp>\n\n\u003Cp>• In response to the question “What do the studies show?”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “The results of a recent double-blind, placebo-controlled, clinical trial has proved the benefits of Collagen Type II for treating the symptoms of pain and immobility associated with arthritis. . . . report an 89.9% positive response rate, within 45 days, for the participants who consumed at least 2000 mg of Collagen Type II per day.”\u003Cbr>\n&nbsp; − “[R]eported having successfully treated more than 50 patients, starting in 1974, with osteoarthritis, rheumatoid arthritis, psoriasis, and many other ailments. . . .”\u003Cbr>\n&nbsp; − “Of the different types of cartilage tested, the one with the highest level of Collagen Type II, anti-inflammatory proteoglycans (the healing properties) was chicken sternal cartilage. CellRenew is 100% chicken sternal cartilage.”\u003C\u002Fp>\n\n\u003Cp>• In response to the question “What else is it good for?”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “Besides the better-known associations with osteoarthritis and rheumatoid arthritis, it has also been suggested that Collagen Type II might benefit heart disease, psoriasis, progressive myopia, and some other autoimmune diseases.”\u003C\u002Fp>\n\n\u003Cp>• In response to the question “How long before I improve?”:&nbsp;&nbsp;\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “Although some people have noticed an improvement with their symptoms after only a week or two of starting a CellRenew program, many take between 4 and 6 weeks. . . . some forms of arthritis symptoms tend to respond faster – on average – than other forms. For instance, we do know that rheumatoid arthritis sufferers have a tendency to respond faster . . .”\u003C\u002Fp>\n\n\u003Cp>Under the heading “CellRenew Customer Stories” on the homepage for the https:\u002F\u002Fappliedhealth.com website:\u003C\u002Fp>\n\n\u003Cp>• “‘I have been taking CellRenew since May of 2003. . . . This product has kept my arthritis at bay. . . .’”\u003C\u002Fp>\n\n\u003Cp>• “‘[T]hank you for the dramatic results I have experienced in the first three weeks of taking CellRenew. For the past twenty years, I have been living with severe lower back pain. I was diagnosed with a degenerative disc disorder in the L2, L3, and L4 vertebrae. . . . CellRenew has improved my quality of life one thousand percent.’”\u003C\u002Fp>\n\n\u003Cp>• “‘Fourteen months ago – diagnosed with scoliosis, osteoarthritis of the spine and degenerative disc disease – my active life was gone . . . I was in excruciating pain most of the time. . . . On the xray [sic], my spine looked like a rock pile. . . . Enter CellRenew, and within one month, the improvement was incredible. That was four months ago. . . . I have my life back. I know that CellRenew works!’”\u003C\u002Fp>\n\n\u003Cp>• “‘I wanted to tell you all about how thrilled I am with CellRenew. I have been taking CellRenew for just over a year now. I have not had a single ache or pain in at least 10 months. I have experienced no side effects, except for one good side effect. I have changed my eyeglass prescription, twice! Both times were for the better! My eyesight is improving. . . .’”\u003C\u002Fp>\n\n\u003Cp>Under the heading “In the beginning…” on the homepage for the https:\u002F\u002Fappliedhealth.com website:\u003C\u002Fp>\n\n\u003Cp>• “Bill Evans, President, Applied Health . . . my lifestyle was finally catching up to me . . . due to rapidly progressing arthritis. . . . Instead of a future filled with the pursuit of my favorite activities, and dreams of conquering the Bucket List, I only saw the prospect of surgeries, painkillers, and physical therapy. I decided there had to be a better way than knee replacement and a cocktail of medications. A year later, in 1997, we started Applied Health and introduced our first Collagen-based, joint support product using hydrolyzed collagen type II . . . We called it CellRenew, and over 20 years later, we still have devoted users . . . [ellipsis in original] myself among them.”\u003C\u002Fp>\n\n\u003Cp>On the “CellRenew Hydrolyzed Collagen Type II Technical Outline” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fcellrenew-technical-outline\u002F):\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Key Product Highlights\u002FBullets”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “CellRenew is so effective that the raw material has been awarded two United States Patents . . . for the treatment of connective tissue disorder, osteoarthritis, degenerative joint disease, joint defects, vascular disease, and cartilage injuries . . .”\u003Cbr>\n&nbsp; − “May help support proper inflammatory function due to its chondroitin sulfate content . . .”\u003Cbr>\n&nbsp; − “May possibly support proper wound healing due to its potent hyaluronic acid content . . .”\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Studies and Mechanisms of action”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “CellRenew and its components can have a powerful impact on joints and conditions associated with abnormal joint function. One study [footnote omitted] published in 2000 entitled ‘Role of collagen hydrolysate in bone and joint disease’, reviews how collagen can be a powerful tool in helping with osteoarthritis and even osteoporosis. . . . Mechanism of action: The components of CellRenew . . . lower the chance for deterioration.”\u003Cbr>\n&nbsp; − “‘[H]yaluronan preparations have been shown to decrease pain and increase function in patients with osteoarthritis of the knee.’ Mechanism of action: Hyaluronic Acid seems to work through several mechanisms of action including restoration of more normal synovial fluid with improved viscoelasticity, effects on cartilage biosynthesis and degradation, anti-inflammatory effects, and direct analgesic effects.”\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Patent Claims”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “2. A method for treating an individual with a connective tissue disorder . . .”\u003Cbr>\n&nbsp; − “3. The method of claim 2, wherein said connective tissue disorder is selected from the group consisting of degenerative joint diseases, joint defects, osteoarthritis, polychondritis, vascular disease, cartilage injuries, progressive myopia and Menier’s [sic] disease.”\u003C\u002Fp>\n\n\u003Cp>On the “Effects of Collagen Type II For Subjective Pain Relief” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fhydrolyzed-collagen-clinical-trial\u002F), which contains a hyperlink to the online storefront where the CellRenewPRO and CellRenewSTS products can be purchased:\u003C\u002Fp>\n\n\u003Cp>• The following quote appears after a summary of a study on the effects of Collagen Type II (an ingredient in CellRenewPRO and CellRenewSTS) on the course of pain syndromes, including rheumatoid arthritic pain, osteoarthritis joint pain, post surgical joint pain, post traumatic pain, fibrositis, gouty arthritis, lumbosacral pain with\u002Fwithout radicular pain, and cervical spine pain with\u002Fwithout radicular pain: “‘The results were overwhelmingly positive for pain relief and the side benefits were remarkable! This product has changed my life significantly.’”\u003C\u002Fp>\n\n\u003Cp>On the “Is Collagen Type II A Cure For Arthritis And Heart Disease?” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fcollagen-type-ii-cure-arthritis-heart-disease\u002F), which hyperlinks to the online storefront where the CellRenewPRO and CellRenewSTS products can be purchased:\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Collagen Type II [an ingredient in CellRenewPRO and CellRenewSTS] and Arthritis”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “. . . 50 million Americans suffer from some form of arthritis, either rheumatoid or osteoarthritis, as well as a variety of other arthritic conditions. . . . Could it be that one nutritional medicine called collagen type II can ameliorate both disorders in an effective way?”\u003Cbr>\n&nbsp; − “It may turn out that the natural components of cartilage hold the greatest promise of ameliorating both arthritis and heart disease.”\u003Cbr>\n&nbsp; − “If collagen type II is derived from chicken sternal cartilage, from chicks six to eight weeks old, it contains the greatest number of anti-inflammatory and joint supporting proteoglycans. These proteoglycans include glucosamine sulfate which has over 30 years of double-blind, placebo-controlled studies indicating that it actually helps to rebuild the cartilage in arthritis joints.”\u003Cbr>\n&nbsp; − “[I]t contains a high concentration of chondroitin sulfate A, which is a powerful anti-inflammatory . . .”\u003Cbr>\n&nbsp; − “[C]ollagen type II also contains a powerful, newly discovered antioxidant proteoglycan called cartilage matrix glycoprotein (CMGP), which can help reduce the oxidative damage to the joint.”\u003Cbr>\n&nbsp; − “When people suffer from arthritis, there is a selective destruction of collagen type II in the joint cartilage itself. Scientists know that this particular component of cartilage is being attacked by white blood cells and somehow this activates the immune system in the rheumatoid arthritic patient to develop antibodies to collagen type II. This then sets up an immune response to all of the cartilage that is degenerating in the body. Thus, both wrists hurt, both knees hurt, the hips, the back, etc.”\u003Cbr>\n&nbsp; − “The question now becomes how does collagen type II turn off the immune system in the rheumatoid arthritic. The answer is that collagen type II’s effectiveness is accomplished through ‘oral tolerance.’”\u003Cbr>\n&nbsp; − “. . . investigate the side effects of chicken sternal collagen type II being fed to arthritic rats. . . . By the second or third months the rats no longer displayed any symptoms of arthritis. There was a profound amelioration of the disease.”\u003Cbr>\n&nbsp; − “. . . studied ten people with severe rheumatoid arthritis. They eliminated the standard therapies such as NSAIDS and methotrexate and fed the patients pure collagen type II derived from chicken sternal cartilage. At the end of the second month, six of the ten patients showed substantial improvement and one showed a complete regression of the disease that lasted 26 months with no side effects.”\u003Cbr>\n&nbsp; − “. . . conducted a phase II trial on 59 patients with, again, severe active rheumatoid arthritis. . . . What is interesting is that those who were off all drugs and taking collagen type II showed very significant stabilization and improvement, while those on placebos continued to deteriorate. In fact, four collagen type II patients showed a complete resolution of the disease . . .”\u003Cbr>\n&nbsp; − “We see that oral ingestion of collagen type II may well prove to be the most effective natural means of arthritis management regardless of the form of the disease.”\u003Cbr>\n&nbsp; − “. . . this is precisely why it works in osteoarthritis . . . collagen type II has such a high concentration of glucosamine and chondroitin . . .”\u003Cbr>\n&nbsp; − “In lieu [sic] of the fact that there are no side effects with collagen type II, this would seem to be the product of choice when suffering from any form of arthritic condition.”\u003Cbr>\n&nbsp; − “. . . collagen II components are truly chondro-protective agents because they . . . reprogram destructive chondrocytes and cytokines, reducing inflammation . . . protect the surface of the cartilage from oxidative damage . . . act as a powerful anti-inflammatory and pain modulator.”\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Collagen Type II [an ingredient in CellRenewPRO and CellRenewSTS] and Heart Disease”:\u003Cbr>\n\u003Cbr>\n&nbsp; − “Medicines such as aspirin and NSAIDS, as well as natural therapeutics such as fish liver oil or antiarthritic herbs, cannot compete with the overall biochemical power of collagen type II.”\u003Cbr>\n&nbsp; − “. . . collagen type II is 14.2 percent chondroitin sulfate A. . . . Chondroitin sulfate A (CSA) has a powerful antithrombogenic or anticoagulant affect, which, in essence, prevents blood clots and has been shown to reduce the incidence of stroke.”\u003Cbr>\n&nbsp; − “. . . CSA literally reduced the cholesterol and other lipids in the blood and actually ‘cleared’ cholesterol from the lining of arteries, including the aorta.”\u003Cbr>\n&nbsp; − “This indicates a 600 percent reduction in the incidence of fatal heart attacks simply by taking oral CSA on a daily basis . . .”\u003Cbr>\n&nbsp; − “Collagen type II has also found some support in the research for the amelioration of autoimmune disease caused by breast implant poisoning, as well as amelioration of Menier’s [sic] disease and progressive myopia.”\u003C\u002Fp>\n\n\u003Cp>On the “The Village of Long Life” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fhyaluronic-acid-abc-news\u002F), which hyperlinks to the online storefront where the CellRenewPRO and CellRenewSTS products can be purchased:\u003C\u002Fp>\n\n\u003Cp>• “. . . hyaluronic acid [a component of the Hydrolyzed Collagen II ingredient in the CellRenewPRO and CellRenewSTS products] has been used for years in eye surgery as a shock absorber to protect the retina, and has been proven effective in lubricating arthritic joints.”\u003C\u002Fp>\n\n\u003Cp>• “But HA has been shown to have wound-healing and tissue-reconstruction applications . . .”\u003C\u002Fp>\n\n\u003Cp>On the “Collagen Type II for Arthritis Pain Relief” blog post (https:\u002F\u002Fappliedhealth.com\u002Fcollagen-type-ii-for-arthritis-pain-relief\u002F):\u003C\u002Fp>\n\n\u003Cp>• “Collagen Type II [an ingredient in the CellRenewPRO and CellRenewSTS products] for Arthritis Pain Relief”\u003C\u002Fp>\n\n\u003Cp>• “Does Collagen Type II relieve osteoarthritis? Research says, yes.”\u003C\u002Fp>\n\n\u003Cp>• “Collagen type II (CTII) is an effective source for alleviating joint stiffness and increasing mobility. Several studies have found CTII reduces joint pain in rheumatoid arthritis, but a new study . . . found that it is also an effective treatment for osteoarthritis.”\u003C\u002Fp>\n\n\u003Cp>• “Researchers recruited 52 subjects with osteoarthritis in the knees to take CTII or a glucosamine\u002Fchondroitin combination for 90 days. . . . Overall, CTII reduced joint pain by 40%.”\u003C\u002Fp>\n\n\u003Cp>• “How does collagen type II alleviate joint pain? CTII is the primary form of collagen naturally found in joint cartilage. The body needs CTII to rebuild connective tissue. Supplementing with a superior form of collagen can help reduce inflammation and the breakdown of collagen in the body. For the best absorption, choose a hydrolyzed collagen type II to restore joint health.”\u003C\u002Fp>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your Applied Health Solutions brand products B Complex, Daily Detox, CellRenewPRO, CellRenewSTS, and the NutriBiotic brand products Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, the B Complex, Daily Detox, CellRenewPRO, CellRenewSTS, Grapefruit Seed Extract CapsulesPlus, and Grapefruit Seed Extract Liquid Concentrate products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to the following address: 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado, 80225-0087, to the attention of Compliance Officer Carrie Jolly or by email to carrie.jolly@fda.hhs.gov. If you need additional information or have questions concerning any products distributed through your website, please contact CO Jolly at carrie.jolly@fda.hhs.gov or (303) 236-9656.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>E. Mark Harris\u003Cbr>\nDenver District Director &amp; Program Division Director\u003Cbr>\nOffice of Human and Animal Food Operations −\u003Cbr>\nDivision IV West\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nWilliam Evans\n\nRecipient Title\n\nPresident\n\nApplied Health Solutions, Inc.\n\n11231 N 84th Street\n\nScottsdale, AZ 85260\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations - Division IV West\n\nUnited States\n\nOctober 22, 2021\n\nWARNING LETTER\n\nRef: CMS Case # 616778\n\nDear Mr. Evans:\n\nThis is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fstore.appliedhealth.com in July-August 2021 and has determined that you take orders there for the Applied Health Solutions brand products B Complex, Daily Detox, CellRenewPRO, CellRenewSTS, and PowerZyme Prime, and the NutriBiotic brand products Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate. We also reviewed your website at the Internet address https:\u002F\u002Fappliedhealth.com, which directs consumers to your website https:\u002F\u002Fstore.appliedhealth.com to purchase your products. The claims on your websites establish these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of the website claims that establish the intended use of the products as drugs include, but may not be limited to, the following:\n\nB Complex product:\n\nOn the “Prevent MRSA Infection” blog post (https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F), which hyperlinks to the product webpage for B Complex:\n\n• “Prevent MRSA Infection . . . Annihilate infections before they start -Strengthen Your Immunity[.] Anything that can be done to boost your immune system will benefit you when you come in contact with this bacteria. . . . make sure you are getting plenty of immune boosting vitamins. . . . B-complex . . .”\n\nDaily Detox product:\n\nOn the Daily Detox product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fcollections\u002Fdetox-cleansing-support\u002Fproducts\u002Fdaily-detox-toxin-binding-agents):\n\n• “Broccoli Extract – BroccoSinolate [an ingredient in Daily Detox] . . . rich in . . . glucosinolates . . . Glucosinolates . . . help lower cancer risks and protect against cardiovascular disease. Another benefit . . . is the ability to help fight bacterial, viral, and fungal infections.”\n\nOn the “Prevent MRSA Infection” blog post (https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F), which hyperlinks to the product webpage for Daily Detox:\n\n• “Regular use of Daily Detox offers powerful antioxidant protection against seasonal colds and flu.”\n\n• “NATURAL TREATMENT: Good riddance “SuperBug”! These nutrients contain anti-microbial and anti-bacterial properties: Applied Health’s Daily Detox . . .”\n\nPowerZyme Prime product:\n\nOn the PowerZyme Prime ingredients webpage (https:\u002F\u002Fappliedhealth.com\u002Fpowerzyme-digestive-enzymes\u002Fpowerzyme-ingredients\u002F):\n\n• “Lysozyme [an ingredient in PowerZyme Prime] . . . Documented in human studies to inhibit the growth of Candida albicans.”\n\n• “Serratia peptidase [an ingredient in PowerZyme Prime] . . . exhibits well documented fibrinolytic (prevention of blood clots), anti-inflammatory, and anti-edematous (prevents swelling of tissues from water entrapment – edema) activities and lessens the viscosity of exudates (a fluid of protein and cellular elements that escapes blood vessels due to inflammation and settles in nearby tissues).”\n\nOn the “Chronic Candida Syndrome” blog post (https:\u002F\u002Fappliedhealth.com\u002Fchronic-candida-syndrome\u002F):\n\n• “What causes Candidiasis? . . . Other contributing factors to Candida imbalance are . . . Lack of digestive enzymes . . .” [the phrase “digestive enzymes” hyperlinks to the PowerZyme Prime product webpage]\n\nOn the “Chronic Candida Syndrome Part 2” blog post (https:\u002F\u002Fappliedhealth.com\u002Fchronic-candida-syndrome-part-2\u002F):\n\n• “Incidence of Candidiasis is rapidly increasing. Several reasons for this are: . . . Lack of proper digestive enzymes in our diet. . . . As always, we prefer to recommend more holistic methods for our readers. However, remember that it is important to rotate even natural therapies, because resistant strains of Candida mutate easily. . . . Nutrients and antioxidants that support the immune system are also important, such as: Digestive Enzymes . . .” [the PowerZyme Prime product is also referred to as “Digestive Enzymes” on the PowerZyme Prime product webpage]\n\nGrapefruit Seed Extract CapsulesPlus product:\n\nOn the Grapefruit Seed Extract CapsulesPlus product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fproducts\u002Fnutribiotic-grapefruit-seed-extract-with-echinacea-and-artemisia-annua):\n\n• “It is effective against pathogens because it belongs to a family of compounds known as quaternary compounds.”\n\n• “Additional information to consider on Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract CapsulesPlus] is available at: Grapefruit Seed Extract for Cold\u002FFlu Season:\n\nhttps:\u002F\u002Fappliedhealth.com\u002Fgrapefruit-seed-extract-rx-for-cold-and-flu-season\u002F . . . Prevent MRSA Infection: https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F . . .”\n\nGrapefruit Seed Extract Liquid Concentrate product:\n\nOn the Grapefruit Seed Extract Liquid Concentrate product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fproducts\u002Fnutribiotic-grapefruit-seed-extract-liquid):\n\n• “Additional information to consider on Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract Liquid Concentrate]: Grapefruit Seed Extract for Cold\u002FFlu Season: https:\u002F\u002Fappliedhealth.com\u002Fgrapefruit-seed-extract-rx-for-cold-and-flu-season\u002F . . . Prevent MRSA Infection: https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F . . .”\n\nGrapefruit Seed Extract Liquid Concentrate and Grapefruit Seed Extract CapsulesPlus products:\n\nOn the “Prevent MRSA Infection” blog post (https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F):\n\n• “NATURAL TREATMENT: Good riddance “SuperBug”! These nutrients contain anti-microbial and anti-bacterial properties . . . Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate]”\n\nOn the “Benefits of Grapefruit seed Extract” webpage (https:\u002F\u002Fappliedhealth.com\u002Fbenefits-of-grapefruit-seed-extract\u002F), which hyperlinks to the Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate product webpages:\n\n• “Grapefruit Seed Extract (GSE) [an ingredient in Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate] . . . Used as a . . . antimicrobial product, it is known to be highly effective for fighting infection . . . Even in studies comparing its effectiveness to chlorine bleach, isopropyl alcohol, and colloidal silver, GSE has been found to be superior as an antimicrobial.”\n\n• “. . . research showing the effectiveness of GSE against AIDS.”\n\n• “All over the world, GSE has been used for killing a wide variety of bacteria (such as: Salmonella, E. coli, Staph and Strep germs), viruses, herpes, parasites, and fungi, including Candida. It is effective against more than 800 bacterial and viral strains, 100 strains of fungus, as well as a large number of single-cell and multi-celled parasites.”\n\n• “. . . the antimicrobial properties of GSE . . .”\n\n• “. . . antifungal properties of GSE have made it an important part of successful anti-Candida programs – a fact that has linked the names Candida and Grapefruit Seed Extract.”\n\n• “‘In the treatment of intestinal protozoan infections . . . [ellipsis in original] drugs are generally so toxic that they cannot be administered for prolonged periods of time, whereas GSE can be administered for weeks or months; prolonged treatment being essential for the cure of chronic protozoan infections . . . [ellipsis in original]’”\n\n• “To aid in the anti-Candida treatment, . . . GSE should be taken between meals. . . .”\n\n• “. . . a variety of other ailments can be helped by GSE, such as: . . .\n\n− AIDS – An increasing number of HIV positive people are able to improve their immune system by using GSE to fight viruses, bacteria, fungi, Candida, or parasites. . . .\n\n− Colds, flus, viruses – Take 10-15 drops, or 1-2 capsules\u002Ftablets, 3 times a day, at the first signs of cold or flu. . . .\n\n− Chronic Fatigue Syndrome – To generally build up immune system, gradually increase GSE amount to the recommended dosage for colds, flus, and viruses. . . .\n\n− Diarrhea – Use 15 to 20 drops in juice every four hours; no more than 60 drops per day. For parasites, higher doses may be necessary. . . .\n\n− Parasites . . .\n\n− Traveler’s Diarrhea (Montezuma’s Revenge) – Use 1-2 drops of GSE in a glass of water each day as a preventative. . . .\n\n− Ulcers . . .”\n\nOn the “Grapefruit Seed Extract Rx for Cold and Flu Season” webpage (https:\u002F\u002Fappliedhealth.com\u002Fgrapefruit-seed-extract-rx-for-cold-and-flu-season\u002F), which hyperlinks to the Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate product webpages:\n\n• “Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate] RX for Cold and Flu Season”\n\n• “A Must-Have For Every Home During Cold and Flu Season”\n\n• “Whether it’s a sore throat, earache, viral infection, intestinal problem, or anything else related to a virus, fungus, or bad bacteria, if you are the main caregiver in your home, Grapefruit Seed Extract is a must-have for your cupboard.”\n\n• “. . . it is ‘Grapefruit’ Seed Extract (abbreviated as GSE or GFSE) that works as a natural antibiotic with anti-viral, anti-bacterial, and anti-fungal properties.”\n\n• Under the heading “Internal Uses”:\n\n− “Fight Colds, Flus, Viruses”\n\n− “Reach for the GSE at the first symptoms of flu or cold.”\n\n− “Traveler’s Diarrhea – As a preventative when traveling in areas with questionable water, mix 1 or 2 drops GSE in each glass of water, or on your toothbrush to disinfect and help prevent Traveler’s diarrhea.”\n\n− “Diarrhea – If you do experience a case of diarrhea, take 15 to 25 drops GSE every 3 to 4 hours in water or juice – no more than 75 drops per day. Or, 2 capsules\u002Ftablets (no more than 6 per day) every 4 hours.”\n\n− “Parasites . . . Use the same amount of GSE as for diarrhea, with possibly increasing to a maximum of 5 doses per day.”\n\n− “There have been anecdotal reports of GSE helping some serious illnesses, such as Chronic Fatigue Syndrome, AIDS, and even Cancer.”\n\n• “There are many more uses for GSE. Once you have successfully used it for something simple, like fighting a cold, you may find yourself reaching for it, regularly, whenever you find a need for its anti-viral, anti-fungal, and anti-bacterial properties.”\n\nCellRenewPRO product:\n\nOn the CellRenewPRO product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fcollections\u002Fjoint-soft-tissue-support\u002Fproducts\u002Fcellrenew-pro-hydrolyzed-collagen-type-ii):\n\n• “CellRenew PRO provides multi-dimensional nutritional components vital for repairing connective soft tissue (joints, skin, cardiovascular, etc.).”\n\nOn the CellRenewPRO supplement facts and monograph webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fpages\u002Fcellrenew-pro-defined):\n\n• “CellRenew Pro is Ultimate Joint Repair”\n\n• “CellRenew PRO provides multi-dimensional nutritional components vital for repairing connective soft tissue (joints, skin, cardiovascular, etc.).”\n\nCellRenewPRO and CellRenewSTS products:\n\nOn the CellRenewPRO (https:\u002F\u002Fstore.appliedhealth.com\u002Fpages\u002Fcellrenew-pro-defined) and CellRenewSTS (https:\u002F\u002Fstore.appliedhealth.com\u002Fpages\u002Fcellrenew-sts-supplement-facts-and-monograph) supplement facts and monograph webpages:\n\n• “CellRenew contains Hydrolyzed Collagen Type II derived from 100% pure chicken sternal cartilage. As an abundant source of naturally-occurring Hyaluronic Acid and Chondroitin Sulfates, Collagen Type II is easily absorbed to restore joint and cartilage health.”\n\n• “It is an absorbable hydrolyzed collagen type II product . . . that . . . relieves joint discomfort and increases mobility.”\n\n• Under the heading “Research”:\n\n− “Collagen Type II (CCII) [an ingredient in CellRenewPRO and CellRenewSTS] . . . can suppress pro-inflammatory activity to reduce joint discomfort and restore cartilage health. CCII from chicken sternal cartilage was shown to reduce chronic joint inflammation . . .”\n\n− “A three-month study recruited 60 patients with chronic joint inflammation to take CCII or a placebo. Results indicated CCII alleviated swollen and tender joints in the treatment group. Four patients in the treatment group had a complete remission of chronic joint inflammation.”\n\n− “Similarly, a pilot-study recruited female subjects with joint pain to take Hydrolyzed Collagen Type II for 42 days. Subjects reported a significant improvement in joint mobility and decrease in joint pain and stiffness.”\n\n− “CCII is evidenced to be effective among adolescents with chronic joint inflammation. A pilot-study administered CCII to 10 adolescent patients with chronic joint inflammation for 12 weeks. Eight patients experienced a reduction in swollen and tender joints. A similar pilot-study recruited nine adolescents with chronic joint inflammation to take an oral Collagen Type II, finding the supplement . . . reduced joint inflammation.”\n\n− “Chondroitin Sulfate (Component of Collagen Type II) [an ingredient in CellRenewPRO and CellRenewSTS] Naturally found in sternal chicken Collagen Type II, chondroitin sulfate has anti-inflammatory activity that reduces joint swelling, maintains synovial fluid levels, and spacing between the joints. Further, chondroitin sulfate reduces the proliferation of proteins to reduce joint inflammation.”\n\n− “A one-year study recruited 42 patients with knee pain to take chondroitin sulfate or a placebo. Subjects taking chondroitin sulfate had greater joint mobility and less pain, when compared to the placebo group.”\n\n− “A three-month study recruited 110 patients with knee pain to take chondroitin sulfate or a placebo finding supplementation improved knee function, reduced pain, and maintained joint space in the knee.”\n\n− “Researchers suggested chondroitin sulfate and glucosamine could repair and regenerate cartilage . . .”\n\n− “Hyaluronic Acid (Component of Collagen Type II) [an ingredient in CellRenewPRO and CellRenewSTS] . . . Studies have suggested hyaluronic acid has anti-inflammatory activity that suppresses pro-inflammatory and pain mechanisms in the body.”\n\n− “Researchers found that HA inhibited inflammatory cytokine activity in mice with inflamed joints. A similar study reviewed the effect of HA on acute and chronic inflammation in rats, finding HA suppressed inflammatory reactions . . .”\n\nOn the homepage for the https:\u002F\u002Fappliedhealth.com website:\n\n• “How do you help knee pain? . . . CellRenew PRO is Extreme Knee Protection”\n\n• “CellRenew Additional Links . . . CellRenew Collagen Type II and Knee Pain . . . Is Collagen Type II A Cure For Arthritis And Heart Disease . . .”\n\n• In the response to the question “What is CellRenew?”:\n\n− “Unlike other protocols for arthritis symptoms, whether prescription or natural, CellRenew is guaranteed for results.”\n\n− “It contains naturally occurring Hyaluronic Acid and Chondroitin Sulfate. The results of a human clinical trial using this material showed significant improvements in the reduction of joint swelling, tenderness, and pain, as well as successful increases in mobility.”\n\n• In the response to the question “Who is a good candidate to take CellRenew?”:\n\n− “Although studies have shown that many different conditions respond to Collagen Type II, the conditions that have shown the greatest response are rheumatoid arthritis and osteoarthritis. If you have grown weary of traditional protocols that only cover-up symptoms and neglect to address the root cause, then you are an excellent candidate to begin a program of Collagen Type II.”\n\n− “CellRenew is also used as a preventative measure for athletes who . . . are looking for a way to maintain healthy joints prior to the onset of osteoarthritis.”\n\n• In response to the question “What will it do for me?”:\n\n− “Collagen Type II (CTII) [an ingredient in CellRenewPRO and CellRenewSTS] has been suggested to offer significant benefits for some types of arthritis. . . . Rheumatoid arthritis (RA) is the most well known of the autoimmune types of arthritis. In the case of RA, the collagen in the joints is attacked.”\n\n− “Depending on the particular type of arthritis you experience, CTII goes to work in different ways. If you suffer from RA, CTII acts as an oral tolerization agent, instructing the body to stop the immune response to the collagen in the joints. . . . For those suffering from osteoarthritis, CTII provides the critical building blocks that restore a healthy state to the cartilage in the joints.”\n\n− “CellRenew is made from chicken sternal cartilage that contains the highest level of naturally occurring anti-inflammatory proteoglycans (Hyaluronic Acid and Chondroitin Sulfate A) of any other material tested, including shark cartilage. It is important to note that the combination of the proteoglycans and the Collagen Type II proteins . . . provide the building blocks required to rebuild lost cartilage to restore the joint to a normal state.”\n\n• In response to the question “What do the studies show?”:\n\n− “The results of a recent double-blind, placebo-controlled, clinical trial has proved the benefits of Collagen Type II for treating the symptoms of pain and immobility associated with arthritis. . . . report an 89.9% positive response rate, within 45 days, for the participants who consumed at least 2000 mg of Collagen Type II per day.”\n\n− “[R]eported having successfully treated more than 50 patients, starting in 1974, with osteoarthritis, rheumatoid arthritis, psoriasis, and many other ailments. . . .”\n\n− “Of the different types of cartilage tested, the one with the highest level of Collagen Type II, anti-inflammatory proteoglycans (the healing properties) was chicken sternal cartilage. CellRenew is 100% chicken sternal cartilage.”\n\n• In response to the question “What else is it good for?”:\n\n− “Besides the better-known associations with osteoarthritis and rheumatoid arthritis, it has also been suggested that Collagen Type II might benefit heart disease, psoriasis, progressive myopia, and some other autoimmune diseases.”\n\n• In response to the question “How long before I improve?”:\n\n− “Although some people have noticed an improvement with their symptoms after only a week or two of starting a CellRenew program, many take between 4 and 6 weeks. . . . some forms of arthritis symptoms tend to respond faster – on average – than other forms. For instance, we do know that rheumatoid arthritis sufferers have a tendency to respond faster . . .”\n\nUnder the heading “CellRenew Customer Stories” on the homepage for the https:\u002F\u002Fappliedhealth.com website:\n\n• “‘I have been taking CellRenew since May of 2003. . . . This product has kept my arthritis at bay. . . .’”\n\n• “‘[T]hank you for the dramatic results I have experienced in the first three weeks of taking CellRenew. For the past twenty years, I have been living with severe lower back pain. I was diagnosed with a degenerative disc disorder in the L2, L3, and L4 vertebrae. . . . CellRenew has improved my quality of life one thousand percent.’”\n\n• “‘Fourteen months ago – diagnosed with scoliosis, osteoarthritis of the spine and degenerative disc disease – my active life was gone . . . I was in excruciating pain most of the time. . . . On the xray [sic], my spine looked like a rock pile. . . . Enter CellRenew, and within one month, the improvement was incredible. That was four months ago. . . . I have my life back. I know that CellRenew works!’”\n\n• “‘I wanted to tell you all about how thrilled I am with CellRenew. I have been taking CellRenew for just over a year now. I have not had a single ache or pain in at least 10 months. I have experienced no side effects, except for one good side effect. I have changed my eyeglass prescription, twice! Both times were for the better! My eyesight is improving. . . .’”\n\nUnder the heading “In the beginning…” on the homepage for the https:\u002F\u002Fappliedhealth.com website:\n\n• “Bill Evans, President, Applied Health . . . my lifestyle was finally catching up to me . . . due to rapidly progressing arthritis. . . . Instead of a future filled with the pursuit of my favorite activities, and dreams of conquering the Bucket List, I only saw the prospect of surgeries, painkillers, and physical therapy. I decided there had to be a better way than knee replacement and a cocktail of medications. A year later, in 1997, we started Applied Health and introduced our first Collagen-based, joint support product using hydrolyzed collagen type II . . . We called it CellRenew, and over 20 years later, we still have devoted users . . . [ellipsis in original] myself among them.”\n\nOn the “CellRenew Hydrolyzed Collagen Type II Technical Outline” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fcellrenew-technical-outline\u002F):\n\n• Under the heading “Key Product Highlights\u002FBullets”:\n\n− “CellRenew is so effective that the raw material has been awarded two United States Patents . . . for the treatment of connective tissue disorder, osteoarthritis, degenerative joint disease, joint defects, vascular disease, and cartilage injuries . . .”\n\n− “May help support proper inflammatory function due to its chondroitin sulfate content . . .”\n\n− “May possibly support proper wound healing due to its potent hyaluronic acid content . . .”\n\n• Under the heading “Studies and Mechanisms of action”:\n\n− “CellRenew and its components can have a powerful impact on joints and conditions associated with abnormal joint function. One study [footnote omitted] published in 2000 entitled ‘Role of collagen hydrolysate in bone and joint disease’, reviews how collagen can be a powerful tool in helping with osteoarthritis and even osteoporosis. . . . Mechanism of action: The components of CellRenew . . . lower the chance for deterioration.”\n\n− “‘[H]yaluronan preparations have been shown to decrease pain and increase function in patients with osteoarthritis of the knee.’ Mechanism of action: Hyaluronic Acid seems to work through several mechanisms of action including restoration of more normal synovial fluid with improved viscoelasticity, effects on cartilage biosynthesis and degradation, anti-inflammatory effects, and direct analgesic effects.”\n\n• Under the heading “Patent Claims”:\n\n− “2. A method for treating an individual with a connective tissue disorder . . .”\n\n− “3. The method of claim 2, wherein said connective tissue disorder is selected from the group consisting of degenerative joint diseases, joint defects, osteoarthritis, polychondritis, vascular disease, cartilage injuries, progressive myopia and Menier’s [sic] disease.”\n\nOn the “Effects of Collagen Type II For Subjective Pain Relief” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fhydrolyzed-collagen-clinical-trial\u002F), which contains a hyperlink to the online storefront where the CellRenewPRO and CellRenewSTS products can be purchased:\n\n• The following quote appears after a summary of a study on the effects of Collagen Type II (an ingredient in CellRenewPRO and CellRenewSTS) on the course of pain syndromes, including rheumatoid arthritic pain, osteoarthritis joint pain, post surgical joint pain, post traumatic pain, fibrositis, gouty arthritis, lumbosacral pain with\u002Fwithout radicular pain, and cervical spine pain with\u002Fwithout radicular pain: “‘The results were overwhelmingly positive for pain relief and the side benefits were remarkable! This product has changed my life significantly.’”\n\nOn the “Is Collagen Type II A Cure For Arthritis And Heart Disease?” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fcollagen-type-ii-cure-arthritis-heart-disease\u002F), which hyperlinks to the online storefront where the CellRenewPRO and CellRenewSTS products can be purchased:\n\n• Under the heading “Collagen Type II [an ingredient in CellRenewPRO and CellRenewSTS] and Arthritis”:\n\n− “. . . 50 million Americans suffer from some form of arthritis, either rheumatoid or osteoarthritis, as well as a variety of other arthritic conditions. . . . Could it be that one nutritional medicine called collagen type II can ameliorate both disorders in an effective way?”\n\n− “It may turn out that the natural components of cartilage hold the greatest promise of ameliorating both arthritis and heart disease.”\n\n− “If collagen type II is derived from chicken sternal cartilage, from chicks six to eight weeks old, it contains the greatest number of anti-inflammatory and joint supporting proteoglycans. These proteoglycans include glucosamine sulfate which has over 30 years of double-blind, placebo-controlled studies indicating that it actually helps to rebuild the cartilage in arthritis joints.”\n\n− “[I]t contains a high concentration of chondroitin sulfate A, which is a powerful anti-inflammatory . . .”\n\n− “[C]ollagen type II also contains a powerful, newly discovered antioxidant proteoglycan called cartilage matrix glycoprotein (CMGP), which can help reduce the oxidative damage to the joint.”\n\n− “When people suffer from arthritis, there is a selective destruction of collagen type II in the joint cartilage itself. Scientists know that this particular component of cartilage is being attacked by white blood cells and somehow this activates the immune system in the rheumatoid arthritic patient to develop antibodies to collagen type II. This then sets up an immune response to all of the cartilage that is degenerating in the body. Thus, both wrists hurt, both knees hurt, the hips, the back, etc.”\n\n− “The question now becomes how does collagen type II turn off the immune system in the rheumatoid arthritic. The answer is that collagen type II’s effectiveness is accomplished through ‘oral tolerance.’”\n\n− “. . . investigate the side effects of chicken sternal collagen type II being fed to arthritic rats. . . . By the second or third months the rats no longer displayed any symptoms of arthritis. There was a profound amelioration of the disease.”\n\n− “. . . studied ten people with severe rheumatoid arthritis. They eliminated the standard therapies such as NSAIDS and methotrexate and fed the patients pure collagen type II derived from chicken sternal cartilage. At the end of the second month, six of the ten patients showed substantial improvement and one showed a complete regression of the disease that lasted 26 months with no side effects.”\n\n− “. . . conducted a phase II trial on 59 patients with, again, severe active rheumatoid arthritis. . . . What is interesting is that those who were off all drugs and taking collagen type II showed very significant stabilization and improvement, while those on placebos continued to deteriorate. In fact, four collagen type II patients showed a complete resolution of the disease . . .”\n\n− “We see that oral ingestion of collagen type II may well prove to be the most effective natural means of arthritis management regardless of the form of the disease.”\n\n− “. . . this is precisely why it works in osteoarthritis . . . collagen type II has such a high concentration of glucosamine and chondroitin . . .”\n\n− “In lieu [sic] of the fact that there are no side effects with collagen type II, this would seem to be the product of choice when suffering from any form of arthritic condition.”\n\n− “. . . collagen II components are truly chondro-protective agents because they . . . reprogram destructive chondrocytes and cytokines, reducing inflammation . . . protect the surface of the cartilage from oxidative damage . . . act as a powerful anti-inflammatory and pain modulator.”\n\n• Under the heading “Collagen Type II [an ingredient in CellRenewPRO and CellRenewSTS] and Heart Disease”:\n\n− “Medicines such as aspirin and NSAIDS, as well as natural therapeutics such as fish liver oil or antiarthritic herbs, cannot compete with the overall biochemical power of collagen type II.”\n\n− “. . . collagen type II is 14.2 percent chondroitin sulfate A. . . . Chondroitin sulfate A (CSA) has a powerful antithrombogenic or anticoagulant affect, which, in essence, prevents blood clots and has been shown to reduce the incidence of stroke.”\n\n− “. . . CSA literally reduced the cholesterol and other lipids in the blood and actually ‘cleared’ cholesterol from the lining of arteries, including the aorta.”\n\n− “This indicates a 600 percent reduction in the incidence of fatal heart attacks simply by taking oral CSA on a daily basis . . .”\n\n− “Collagen type II has also found some support in the research for the amelioration of autoimmune disease caused by breast implant poisoning, as well as amelioration of Menier’s [sic] disease and progressive myopia.”\n\nOn the “The Village of Long Life” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fhyaluronic-acid-abc-news\u002F), which hyperlinks to the online storefront where the CellRenewPRO and CellRenewSTS products can be purchased:\n\n• “. . . hyaluronic acid [a component of the Hydrolyzed Collagen II ingredient in the CellRenewPRO and CellRenewSTS products] has been used for years in eye surgery as a shock absorber to protect the retina, and has been proven effective in lubricating arthritic joints.”\n\n• “But HA has been shown to have wound-healing and tissue-reconstruction applications . . .”\n\nOn the “Collagen Type II for Arthritis Pain Relief” blog post (https:\u002F\u002Fappliedhealth.com\u002Fcollagen-type-ii-for-arthritis-pain-relief\u002F):\n\n• “Collagen Type II [an ingredient in the CellRenewPRO and CellRenewSTS products] for Arthritis Pain Relief”\n\n• “Does Collagen Type II relieve osteoarthritis? Research says, yes.”\n\n• “Collagen type II (CTII) is an effective source for alleviating joint stiffness and increasing mobility. Several studies have found CTII reduces joint pain in rheumatoid arthritis, but a new study . . . found that it is also an effective treatment for osteoarthritis.”\n\n• “Researchers recruited 52 subjects with osteoarthritis in the knees to take CTII or a glucosamine\u002Fchondroitin combination for 90 days. . . . Overall, CTII reduced joint pain by 40%.”\n\n• “How does collagen type II alleviate joint pain? CTII is the primary form of collagen naturally found in joint cartilage. The body needs CTII to rebuild connective tissue. Supplementing with a superior form of collagen can help reduce inflammation and the breakdown of collagen in the body. For the best absorption, choose a hydrolyzed collagen type II to restore joint health.”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Applied Health Solutions brand products B Complex, Daily Detox, CellRenewPRO, CellRenewSTS, and the NutriBiotic brand products Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, the B Complex, Daily Detox, CellRenewPRO, CellRenewSTS, Grapefruit Seed Extract CapsulesPlus, and Grapefruit Seed Extract Liquid Concentrate products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to the following address: 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado, 80225-0087, to the attention of Compliance Officer Carrie Jolly or by email to carrie.jolly@fda.hhs.gov. If you need additional information or have questions concerning any products distributed through your website, please contact CO Jolly at carrie.jolly@fda.hhs.gov or (303) 236-9656.\n\nSincerely,\n\n\u002FS\u002F\n\nE. Mark Harris\n\nDenver District Director & Program Division Director\n\nOffice of Human and Animal Food Operations −\n\nDivision IV West","Applied Health Solutions, Inc.","applied-health-solutions-inc-616778-10222021","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fapplied-health-solutions-inc-616778-10222021","2026-10-26T08:07:56.864908+00:00","2022-02-01","616778","William Evans","2026-08-20T02:12:48.529+00:00","2021-10-22",6,{"510k":136,"classification":137,"enforcement":138,"event":139,"event_backfill":140,"pma":141,"warning_letter":142},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]